#### 1 High-resolution molecular atlas of a lung tumor in 3D

- 2 Tancredi Massimo Pentimalli<sup>1,2</sup>, Simon Schallenberg<sup>3</sup>, Daniel León-Periñán<sup>1</sup>, Ivano
- 3 Legnini<sup>1,4</sup>, Ilan Theurillat<sup>1</sup>, Gwendolin Thomas<sup>1</sup>, Anastasiya Boltengagen<sup>1</sup>, Sonja Fritzsche<sup>5</sup>,
- 4 Jose Nimo<sup>5</sup>, Lukas Ruff<sup>6</sup>, Gabriel Dernbach<sup>3,6,7</sup>, Philipp Jurmeister<sup>8</sup>, Sarah Murphy<sup>9</sup>, Mark T.
- 5 Gregory<sup>9</sup>, Yan Liang<sup>9</sup>, Michelangelo Cordenonsi<sup>10</sup>, Stefano Piccolo<sup>10,11</sup>, Fabian Coscia<sup>5</sup>,
- 6 Andrew Woehler<sup>12,13</sup>, Nikos Karaiskos<sup>1</sup>, Frederick Klauschen<sup>2</sup>, Nikolaus Rajewsky<sup>1, 13, 14, 15</sup>,
- 7 16, 17\*
- 8 <sup>1</sup>Laboratory for Systems Biology of Regulatory Elements, Berlin Institute for Medical
- 9 Systems Biology (BIMSB), Max-Delbrück-Centrum for Molecular Medicine in the
- 10 Helmholtz Association (MDC), Hannoversche Str. 28, 10115 Berlin
- <sup>11</sup> <sup>2</sup> Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and
- 12 Humboldt- Universität zu Berlin, Berlin School of Integrative Oncology (BSIO), Charitéplatz
- 13 1, 10117 Berlin, Germany
- <sup>3</sup> Institute of Pathology, Charité Universitätsmedizin Berlin, corporate member of Freie
- 15 Universität Berlin and Humboldt-Universität Berlin, 10117 Berlin, Germany
- <sup>4</sup> Human Technopole, Palazzo Italia, Viale Rita Levi-Montalcini 1,20157 Milan, Italy
- 17 <sup>5</sup> Spatial Proteomics Group, Max-Delbrück-Centrum for Molecular Medicine in the
- 18 Helmholtz Association (MDC), Berlin, 13125 Germany
- <sup>6</sup> Aignostics GmbH, 10555 Berlin, Germany
- <sup>7</sup> BIFOLD Berlin Institute for the Foundations of Learning and Data, Berlin, Germany.
- 21 <sup>8</sup> Institute of Pathology, Ludwig-Maximilians-Universität, München
- <sup>9</sup> NanoString® Technologies, Inc., Seattle, WA 98109, USA
- <sup>10</sup> Department of Molecular Medicine, University of Padua, Padua, Italy
- <sup>11</sup> IFOM ETS, the AIRC Institute of Molecular Oncology, Milan, Italy

- 1 <sup>12</sup> Systems Biology Imaging Platform, Berlin Institute for Medical Systems Biology
- 2 (BIMSB), Max-Delbrück-Centrum for Molecular Medicine in the Helmholtz Association
- 3 (MDC), 10115 Berlin, Germany
- 4 <sup>13</sup> Howard Hughes Medical Institute, Janelia research campus, 19700 Helix Drive, Ashburn,
- 5 Virginia 20147
- 6 <sup>14</sup> Charité Universitätsmedizin, Charitépl. 1, 10117 Berlin, Germany
- 7 <sup>15</sup> German Center for Cardiovascular Research (DZHK), Site Berlin, Berlin, Germany
- 8 <sup>16</sup> NeuroCure Cluster of Excellence, Berlin, Germany
- 9 <sup>17</sup> German Cancer Consortium (DKTK)
- 10 <sup>18</sup> National Center for Tumor Diseases (NCT), Site Berlin, Berlin, Germany
- 11 \*Corresponding author

### 1 ABSTRACT

2 Cells live and interact in three-dimensional (3D) cellular neighborhoods. However, histology 3 and spatial omics methods mostly focus on 2D tissue sections. Here we present a 3D spatial 4 atlas of a routine clinical sample, an aggressive human lung carcinoma, by combining *in situ* 5 quantification of 960 cancer-related genes across ~340,000 cells with measurements of tissue-6 mechanical components. 3D cellular neighborhoods subdivided the tumor microenvironment 7 into tumor, stromal, and immune multicellular niches. Interestingly, pseudotime analysis 8 suggested that pro-invasive epithelial-to-mesenchymal transition (EMT), detected in stroma-9 infiltrating tumor cells, already occurred in one region at the tumor surface. There, 10 myofibroblasts and macrophages specifically co-localized with pre-invasive tumor cells and 11 their multicellular molecular signature identified patients with shorter survival. Moreover, 12 cytotoxic T-cells did not infiltrate this niche but colocalized with inhibitory dendritic and 13 regulatory T cells. Importantly, systematic scoring of cell-cell interactions in 3D 14 neighborhoods highlighted niche-specific signaling networks accompanying tumor invasion 15 and immune escape. Compared to 2D, 3D neighborhoods improved the characterization of 16 immune niches by identifying dendritic niches, capturing the 3D extension of T-cell niches 17 and boosting the quantification of niche-specific cell-cell interactions, including druggable immune checkpoints. We believe that 3D communication analyses can improve the design of 18 19 clinical studies investigating personalized, combination immuno-oncology therapies.

#### 1 INTRODUCTION

2 Cells build three-dimensional (3D) tissues to perform specific functions. Mechanical cues and 3 molecular signaling regulating tissue development and function operate in 3D between 4 neighboring cells. The comprehensive characterization of 3D cellular neighborhoods in terms 5 of cellular composition, molecular states, mechanical properties and ligand-receptor 6 interactions is thus central to understand tissue function in health and disease. While light 7 microscopy [1] and hematoxylin and eosin (H&E) staining [2] enabled the morphological 8 characterization of tissue organization in 3D, the molecular exploration of 3D cellular 9 neighborhoods is still in its infancy.

10 Recent developments in spatial omics methods profoundly changed our ability to characterize tissue molecular properties [3]. While STARmap [4] and DISCO-MS [5] enabled the 3D 11 profiling of intact mouse tissues, ad hoc tissue processing hinders their application to 12 13 routinely collected fresh-frozen (FF) and formalin-fixed paraffin-embedded (FFPE) clinical 14 samples. Therefore, the initial molecular studies leveraged the computational registration of 15 sequential 2D sections for the *in silico* reconstruction of tissue architecture in 3D. These 16 included the imaging mass cytometry (IMC) study of breast cancer (40 proteins in 3 samples) [6] and the multiplexed immunofluorescence (IF) study of colorectal cancer (32 proteins in 1 17 18 sample) [7]. While enabling single cell-resolved tissue profiling, these methods are limited in 19 plexity, only measuring tens of proteins at the time. Conversely, sequencing-based spatial 20 transcriptomics methods, such as Slide-seq [8], ST [9] (now Visium) and Stereo-seq [10], which rely on the capture of polyadenylated transcripts on spatially barcoded regions, enabled 21 22 the unbiased, genome-wide characterization of 3D gene expression patterns in the mouse 23 hippocampus (10  $\mu$ m beads) [8], rheumatoid arthritis synovium (100  $\mu$ m spots) [11] and 24 developing Drosophila embryo (10 µm x 10µm or 25 µm x25 µm bins) [12]. However, intrinsic resolution limits and difficulties in assigning regions to single cells prevented single-25 26 cell resolved analyses. Furthermore, polyA-based methods require intact RNA molecules (as in FF tissues) for efficient transcript capture, thus preventing their application to fragmented 27 28 RNA typical of FFPE clinical samples. On the other hand, high-plex imaging-based spatial 29 transcriptomic methods, such as MERFISH [13] and CosMx [14], use probes to recognize 30 their targets with single molecule resolution, are compatible with both FF and FFPE tissues 31 but have not yet been used for the 3D reconstruction of clinical specimens.

1 Here we present the 3D, high-plex and single-cell resolved molecular atlas of a human tissue, 2 enabling the reconstruction, multimodal profiling and systematic exploration of 3D cellular 3 neighborhoods using CosMx. For this proof-of-principle study, we focused on an aggressive, 4 early-stage non-small cell lung cancer (NSCLC) sample and investigated the ability of 3D 5 neighborhoods to identify tumor invasion and immune escape mechanisms active in the 6 patient under study. Despite being a paradigm of precision medicine with an arsenal of 7 molecularly targeted therapies and immunotherapy agents [15], NSCLC remains the main cause of cancer-related death [16]. Furthermore, only 20% of NSCLC patients respond to 8 9 immunotherapy [17] and up to 30% of treated patients suffer from immune-related adverse 10 events [18]. Therefore, the identification of personalized immunotherapy biomarkers 11 represents an urgent unmet clinical need to maximize therapeutic efficacy and limit toxicity in 12 NSCLC.

13 As DNA sequencing guides the administration of targeted therapies through the detection of 14 druggable mutations [19], spatial omics methods hold great promise for the identification of 15 immune escape mechanisms active in individual patients, which could serve as personalized 16 (immune)therapy biomarkers. Here we showcase the power of high-plex, single cell resolved, 17 molecular histology to simultaneously profile cell types, molecular states, and receptor-ligand interactions underlying tumor invasion and immune escape. Importantly, we demonstrate how 18 19 3D neighborhoods improved the identification of tumor immune escape mechanisms, 20 compared to their 2D counterparts.

# 21 **RESULTS**

# 22 1. Multimodal study of one aggressive NSCLC tumor in 3D

23 For this proof-of-principle study, we selected an early-stage NSCLC patient, which

24 demonstrated rapid disease progression and aggressive tumor biology (Ext data fig 1a). To

25 reconstruct 3D cellular neighborhoods, we cut 34 consecutive 5 μm-thick tissue sections from

26 a routinely collected, archival FFPE tumor block. We leveraged deep-learning based

27 classification of tumor, stromal and normal lung-resident compartments in one whole-slide

H&E image to select one 16 mm<sup>2</sup> wide region of interest (ROI) featuring the copresence of

29 both the primary tumor and cancer-associated stroma for spatial transcriptomics investigation

30 (Ext data fig 1b). Furthermore, we reasoned that the presence of small-caliber airways

1 crossing the section planes would enable the assessment of section alignments in 3D. We then

2 collected single-cell resolved spatial transcriptomics data from every 6<sup>th</sup> section (30µm

3 section-to-section interval) and profiled intervening sections with complementary modalities,

4 enabling the integrative analysis of tissue morphology, ECM composition, protein markers

5 and gene expression (Fig 1a).

### 6 2. Molecular histology of the tumor microenvironment at single-cell resolution

- 7 To gain insights into the spatial organization and crosstalk between tumor, stromal and
- 8 immune populations, we performed 1000-plex RNA in situ hybridization (ISH) with CosMx
- 9 Spatial Molecular Imager and leveraged deep-learning based cell segmentation of IF staining

10 of nuclei and plasma membranes to obtain single cell gene expression profiles (Methods). We

11 profiled 960 cancer-related genes allowing the simultaneous characterization of cellular

12 identities (211 genes), transcriptomic states (268 genes), and cell-to-cell communication

13 events (517 genes) in the TME [14] (Supplementary table 1).

14 We imaged a total of 155,055,865 transcripts distributed in six sequential, non-consecutive

15 ROIs (Ext data fig 1c). 20 negative probes (i.e. targeting sequences not present in human

16 tissues) composed only 0.27% of the total detected molecules, demonstrating highly specific

17 *in-situ* detection of target genes. To further assess data quality, we confirmed the

18 colocalization of pancytokeratin (panCK) staining and ISH signal for KRT19 transcripts in the

same section (Fig 1b). 74.1% of the detected transcripts were assigned to 340,644 segmented

20 cells (101 median genes and 198 median transcripts/cell). Near-perfect correlations of total

21 transcript counts confirmed robust gene expression profiling across sections (Ext data fig

1d). Furthermore, hierarchical clustering recapitulated the spatial arrangement as sections

23 closer in the z-axis showed slightly higher correlations than distant ones.

24 Through unsupervised clustering of gene expression in segmented cells (Ext data fig 1e), we

25 identified 18 cell types (Fig 1c) based on the expression of canonical marker genes (Ext data

26 **fig 1f**) and IF positivity to panCK staining (**Ext data fig 1g**). In line with previous reports

27 [20], tumor cells were characterized by a larger cell size and higher transcript counts (Ext

28 **data fig 1g**). Transferring cell type annotations back to their tissue positions, we observed

29 their correspondence with the spatial patterns of epithelial, stromal and immune populations

30 observed using routine histology (Fig 1d, Ext data fig 1h-i). Comparing gene expression of

1 segmented cells with published single-cell RNA sequencing atlases, we confirmed the

2 agreement of our cell type annotations with healthy lung [21] and NSCLC atlases [22] (Fig

3 1e).

4 In summary, we generated a high-quality, single cell-resolved molecular atlas of the TME,

- 5 including more than 340,000 cells spanning 18 epithelial, stromal and immune cell types and
- 6 went on to explore their 3D cellular neighborhoods.

# 7 **3. Reconstruction of 3D cellular neighborhoods**

8 To reconstruct 3D cellular neighborhoods, we leveraged STIM [23], which employs state-of-

9 the-art computer vision techniques, to computationally align spatial transcriptomics data and

10 generate a 3D molecular map of the TME at single-cell resolution. Supporting the high

11 fidelity of our 3D model, visualization of respiratory epithelium cells revealed that the

12 successful reconstruction of airway lumen moving along the individual 2D planes (Fig 2a).

13 We thus went on to define 3D neighborhoods for each cell as a spherical space encompassing

14 all cells located within a 50 µm center-to-center distance (**Fig 2b**). By design, 3D cellular

15 neighborhoods included both a circular 314.16  $\mu$ m<sup>2</sup> area in the section where the center cell is

16 located and two 251.33  $\mu$ m<sup>2</sup> areas in the sections immediately above and below in the z plane,

17 which represents a 2.6-fold increase compared to the study of 2D cellular neighborhoods.

18 Owing to the precise positioning of the ROIs during data collection, relatively minor

19 transformations were required for 3D image registration (Ext data fig 2a). Nevertheless, the

20 median shift of cell positions after registration was  $\sim$ 42 µm, which would have altered 3D

21 cellular neighborhoods if uncorrected.

22 After excluding cells whose neighborhoods extended beyond the boundaries of the 3D

23 reconstruction (i.e., located in the first/last sections or within 50 µm from the edge of the

central sections), we set out to study the 3D neighborhoods for 218,378 center cells.

25 Quantification of 3D neighborhood cell type composition (Fig 2b) revealed the complexity

26 and richness of cellular microenvironments (median of 71 cells from 9 cell

27 types/neighborhood). In comparison, 2D neighborhoods featured not only a reduced number

28 of neighbors but also a lower cell type richness (median of 32 cells from 7 cell

29 types/neighborhood) and a lower alpha diversity – a common measure of species richness in

30 ecology studies – (median Chao index 3D: 10.5 vs 2D: 8) (Ext data fig 2b).

# 4. 3D neighborhoods enable the unbiased identification of multicellular niches in the TME

3 Cellular activities and molecular profiles are shaped by the surrounding tissue 4 microenvironment [3]. To group cells sharing the same tissue microenvironment, we 5 unbiasedly clustered center cells based on their 3D neighborhood cellular composition -6 regardless of their gene expression-. In this way, we identified 10 TME niches (Fig 2c), 7 defined as multicellular compartments sharing a specific neighborhood composition (Fig 2d). 8 These comprised both lung-resident epithelial (i.e. 'airways' and 'alveoli') and stromal (i.e. 9 'smooth muscle') niches and TME-specific tumor, stromal and immune niches. High numbers 10 of tumor cells characterized the 3D neighborhoods of cells assigned to both 'tumor core' and 11 the 'tumor surface'. The tumor core featured a higher cellular density but a lower cellular 12 diversity (Ext data fig2c) as 3D neighborhoods were dominated by tumor cells. On the other 13 hand, the tumor surface featured a higher count of fibroblasts, macrophages and cytotoxic T 14 cells, resulting in a higher cell type diversity compatible with its position at the boundary with 15 the surrounding stroma. 3D neighborhoods not only distinguished the 'vascular stroma' - rich 16 in vascular endothelium and pericytes - from the 'desmoplastic stroma', featuring the highest 17 fibroblast and plasma cell density, but also identified 3 distinct immune niches. Interestingly, tumor cells were abundant in 3D neighborhoods of 'dendritic cell niches' and 'macrophages 18 19 niches' but not in 'T cell niches'. Mapping niche annotations back to their tissue positions 20 revealed that T cell niches were mainly found in proximity of larger airways or dispersed in 21 the stroma. On the other hand, macrophage niches and dendritic cell niches were embedded in 22 the tumor surface (Fig 2e), thus explaining the abundance of tumor cells in these niches and 23 suggesting their functional role in the local regulation of anti-tumoral immune responses. 24 Furthermore, comparison with manual annotations of routine H&E histology by an 25 experienced pathologist (S.S.) confirmed the ability of 3D neighborhoods to capture the TME 26 spatial organization (Ext data fig2d).

We then sought to evaluate the ability of 3D neighborhoods to capture the TME spatial organization compared to their 2D counterparts. While 2D niches largely corresponded to 3D ones and even included a 'macrophage-rich stroma' (**Ext data fig2e**), 2D neighborhoods did not highlight 'dendritic niches'. While the 2D and 3D niche assignments agreed for 64.1% of cells, concordance rates varied across niches (**Fig 2f**). In particular, 'tumor core' and 'T cell niches' showed below average concordance rates as around 50% of cells assigned to these

1 niches in 3D were reassigned in 2D to the 'desmoplastic stroma' and 'tumor surface',

2 respectively. Consequently, the abundance of 'T cell niches' and 'tumor core' was reduced in

3 2D compared to 3D. Importantly, 'T cell niches' and 'tumor core' formed smaller

4 disconnected patches in 2D and most of the cells unique to the 3D analysis formed bridges

5 across patches, restoring the spatial continuity of these niches (Fig 2g).

6 In summary, we generated a 3D molecular atlas of the TME and leveraged it to study 3D

7 neighborhoods for over 200,000 cells. Remarkably, the unbiased analysis of cell type

8 abundance in 3D neighborhoods decomposed the TME into 10 distinct multicellular niches,

9 corresponding to expert annotations of morphological tissue structures. While 2D niches

10 largely agreed with their 3D counterparts, 3D neighborhoods improved the identification of

11 immune niches in the TME and better captured their 3D spatial continuity.

#### 12 5. Tumor cells acquire pro-invasive molecular programs in the EMT niche

13 The ability of cancer cells to detach from the epithelial sheet and infiltrate the adjacent stroma

14 (i.e. "invasiveness") is a hallmark of malignant tumors and essential for metastatic

15 dissemination [24]. At the molecular level, the downregulation of cell-to-cell adhesion

16 molecules (i.e. *EPCAM* and *CDH1*) and the upregulation of mesenchymal markers (i.e. *VIM*)

17 during epithelial-to-mesenchymal transition (EMT) promotes the invasion of surrounding

18 tissues [25]. Quantifying the niche assignments of 38,804 tumor cells, we noted that, while

19 most tumor cells were located in the tumor bed, more than 9,000 tumor cells were assigned to

20 other tissue niches (Ext data fig3a). Comparing the observed and expected number of

21 infiltrating tumor cells (Methods), we identified their preferential infiltration of 'macrophage

22 niches', 'dendritic cell niches', 'desmoplastic stroma' and 'alveolar spaces' (Ext data fig3b).

23 Through 3D rendering, we demonstrate how the 'tumor surface' precisely interlocked and

24 covered the 'tumor core' and studied the spatial distribution of infiltrating tumor cells (Fig

25 **3a**). While the spatial continuity of the 'tumor surface' with 'macrophage niches', 'dendritic

26 cell niches' and 'alveoli' could explain the enrichment of tumor cells in these niches (Supp

27 Video 1), tumor cells the 'desmoplastic stroma' extended away from the tumor surface (Fig

28 **3b**). We thus focused on these cells to identify molecular pathways activated upon tumor

29 invasion.

1 Comparing the transcriptomic profiles of tumor cells in the 'desmoplastic stroma' against 2 those in the 'tumor core', we detected the upregulation of cytokeratins (KRT19, KRT17 and 3 *KRT6A*) (Fig 3c), which was validated at the protein level by a stronger panCK IF signal (Ext 4 data fig3c). Consistent with EMT, VIM expression was upregulated in infiltrating tumor cells 5 while EPCAM and CDH1 were downregulated. Interestingly, tumor cells assigned to the 6 'tumor surface' already demonstrated such molecular changes - albeit to a lesser extent - (Ext 7 data fig 3d). This is consistent with the view that EMT is a complex, continuous process with 8 a spectrum of intermediate states between a fully epithelial and a fully mesenchymal 9 phenotype [26]. Therefore, we leveraged pseudotime, a popular approach in the single cell 10 transcriptomics field to reconstruct dynamic molecular processes, to rank tumor cells from 0 11 (early) to 1 (late) (Fig 3d). Pseudotime captured EMT dynamics as tumor cells with higher epithelial markers (i.e. CDH1<sup>high</sup> EPCAM<sup>high</sup> VIM<sup>low</sup>) showed earlier pseudotime, while 12 pseudotime increased in cells undergoing EMT (i.e. CDH1<sup>low</sup> EPCAM<sup>low</sup> VIM<sup>high</sup>) (Fig 3e, 13 Ext data fig 3e-f). Combining tumor pseudotime and 3D niche assignments, we demonstrate 14 15 the progressive activation of an EMT gene expression program from tumor core, over tumor surface, to stroma infiltrating tumor cells (median pseudotime scores: 0.39, 0.50 and 0.85) 16 17 (Ext data fig 3g). We then evaluated the 3D spatial density of pseudotime scores and confirmed that infiltrating tumor cells feature both an advanced pseudotime and 18 19 'pseudospace' (intended as distance from the tumor bed), while tumor cells in the tumor core 20 by both an early pseudotime and pseudospace (given their location in the tumor bed). 21 Strikingly, we discovered one regionat the interface between the 'tumor surface' and the 'desmoplastic stroma' where the density of mesenchymal-like tumor cells peaked (Fig 3f, Ext 22 23 data fig 3h) and IF validated the presence of panCK+ CDH1<sup>low</sup> cells (Ext data fig 3i). Intriguingly, the EMT niche was characterized by the discrepancy between pseudotime 24 25 (advanced) and pseudospace (early), indicating that tumor cells may undergo EMT already in 26 the tumor bed before invading the desmoplastic stroma.

# 6. A multicellular molecular signature links the EMT niche with reduced survival in a large cohort

- 29 Molecular understanding of tumor invasion is critical for identifying biomarkers to accurately
- 30 predict and intercept tumor progression [27]. Investigating tumor-intrinsic molecular
- 31 programs active in the 'EMT niche' (Fig 4a), we identified *LGALS1* and *NDRG1* as the genes
- 32 with the strongest differential expression (Fig 4b). *LGALS1* (Galectin-1) is known to be

1 upregulated in NSCLC compared to healthy lung tissues [28] and to promote tumor cell EMT

2 and immune escape [29], while *NDRG1* (N-myc downstream-regulated gene 1) promotes

3 stem-like properties in NSCLC cells [30]. Remarkably, their expression was not only enriched

4 but almost spatially restricted to tumor cells in the 'EMT niche' (Fig 4c, Ext data fig 4a).

5 In light of *LGALS1* role in microenvironment remodeling, we investigated whether the cell

6 type composition of the 'EMT niche' differed from the rest of TME. While tumor cells were

7 the most abundant cell type, they composed only 33.1% of the 'EMT niche' (**Fig 4d**).

8 Fibroblasts and macrophages were the main enriched cell types (Ext data fig4b) and, together

9 with tumor cells, formed 83.8% of the 'EMT niche'. We thus focused on fibroblasts and

10 macrophages differentially expressed genes to identify tumor-extrinsic molecular programs

11 active in the 'EMT niche'.

12 Fibroblasts upregulated *IGFBP5* and *VEGFA* (Fig 4e) and their expression was highly

13 specific to the 'EMT niche' (Fig 4f, Ext data fig 4c). *IGFBP5* (Insulin Growth Factor

14 Binding Protein-5) acts as a reservoir of IGF ligands in the ECM [31] and, especially in the

15 presence of FN1, potentiates IGF signaling, a key pathway promoting cancer cell EMT,

16 proliferation and stemness [32]. Therefore, the local upregulation of *FN1* (Fibronectin-1) and

17 downregulation of *IGFBP7* (Insulin Growth Factor Binding Protein-7), which blocks IGF1R

18 activation [33], could further contribute to the local stimulation of pro-invasive IGF signaling

19 by fibroblasts in the 'EMT niche' (**Ext data fig 4d-e**).

20 At the same time, VEGFA (Vascular Endothelial Growth Factor) is a key factor in

21 orchestrating TME remodeling, promoting angiogenesis and the recruitment of tumor-

22 associated macrophages [34]. While the density of capillaries– marked by vascular

23 endothelium and pericytes - was among the lowest in the TME (**Ext data fig4f**), macrophage

24 density peaked in the 'EMT niche' (Ext data fig4g). Interestingly, macrophages upregulated

25 the expression of *VIM* - expressed by activated macrophages [35]- and the M2 polarization

26 marker *GLUL* (Glutamine synthase) [36] (**Fig 4g**), compatible with a pro-tumorigenic

27 phenotype. In addition, the expression of SPP1 (Secreted Phosphoprotein-1), a potent

28 chemoattractant for both tumor cells and macrophages that induces the growth of metastatic

29 tumors in a preclinical NSCLC model [37], was highly specific to macrophages in the 'EMT

30 niche' (**Fig 4h**).

1 As tumor invasion typically precedes metastasis to distal organs -the main cause of cancer-

- 2 related death -, we went on to investigate whether the molecular programs localized to the
- 3 'EMT niche' were linked with patient survival in a large NSCLC cohort. We leveraged the
- 4 paired transcriptomic (bulk RNAseq) and survival data for 503 lung adenocarcinoma patients
- 5 in The Cancer Genome Atlas to investigate the prognostic role of genes specifically expressed
- 6 in the 'EMT niche' (difference of expressing cells > 25%). While single gene enrichments
- 7 identified patients with a worse prognosis (hazard ratios HR >1), their effects were never
- 8 statistically significant (**Ext data fig4h-n**). On the other hand, a multicellular signature
- 9 combining tumor (LGALS1 and NDRG1), fibroblast (IGFBP5 and VEGFA) and macrophage
- 10 specific (SPP1) genes robustly identified patients with shorter overall survival (Fig 4i).
- 11 Furthermore, *NDRG1* was recently identified as the most specific marker of early brain
- 12 metastasis (<10 months after diagnosis) in NSCLC patients [38], which matches the clinical
- 13 history of the patient under study (brain metastasis 11 months after diagnosis).
- 14 Taken together, the 'EMT niche' represents a specialized compartment enriched with pre-
- 15 invasive tumor cells, fibroblast and macrophages. Strikingly, the combination of multicellular
- 16 molecular programs spatially restricted to this niche identified patients with poor prognosis,
- 17 linking this niche with tumor progression.

# 7. Fibroblast molecular states are linked with the extracellular matrix and cellular composition of their 3D neighborhoods

20 Tissue stiffening is a hallmark of tumorigenesis, promoting both malignant transformation, 21 EMT and invasion [39]. Thus, we investigated whether tissue biomechanical properties could 22 explain the enrichment of mesenchymal-like tumor cells in the 'EMT niche'. Quantifying the 23 ECM composition in 3D neighborhoods via second harmonic generation imaging (SHG) (Fig 24 5a, Methods), we confirmed the presence of a homeostatic elastin-rich ECM surrounding 25 lung-resident populations, such as basal and alveolar cells, while fibroblasts and plasma cells 26 lived in a collagen-rich (i.e. desmoplastic) ECM (Ext data fig 5a). Compatible with ECM 27 degradation, tumor cell neighborhoods featured the lowest elastin and collagen signals. Taken 28 together, while collagen deposition, which is the main determinant of tissue tension [40], may 29 sustain EMT in tumor cells infiltrating the desmoplastic stroma, it cannot explain EMT 30 induction in the 'EMT niche', which featured a collagen-poor ECM similar to the rest of the tumor bed (Fig 5b). 31

1 Searching for other factors that could induce/sustain tumor EMT, we shifted our focus 2 towards fibroblasts, which were abundant and upregulated pro-invasive molecular programs 3 in the 'EMT niche'. The unbiased study of molecular phenotypes for 62,604 fibroblasts 4 revealed six transcriptomic states (Fig 5c), which we annotated through literature-informed 5 review of their marker genes (Ext data fig5b). Multimodal profiling linked fibroblast 6 molecular states with the mechanical properties and cellular composition of their 3D 7 neighborhoods (Ext data fig5c-e). For example, JUN+ FOS+ IGF1+ 'activated fibroblasts' were enriched in the desmoplastic stroma and surrounded by a collagen-rich ECM, while 8 9 CD74+ HLA-DRB1+ 'antigen-presenting', TIMP1+ CCL19+ 'reticular' and TIMP1+ CXCL10+ 'reticular' fibroblasts lived in a homeostatic ECM and were spatially enriched in 10 immune niches. On the other hand, FN1+ COL11A1+ ACTA2+ 'myofibroblasts' were 11 12 surrounded by a collagen- and elastin-depleted ECM. Strikingly, they were spatially restricted 13 the tumor bed and their density peaked in the EMT niche (Fig 5d). Compared to other fibroblast states, myofibroblasts upregulated 'EMT niche' secreted factors (IGFBP5 and 14 15 VEGFA), ECM-remodeling (FN1 and COL11A1) and smooth muscle-specific contractile proteins (TAGLN and ACTA2) (Ext data fig 5b,f). Similar to wound healing [41], 16 17 myofibroblast contraction - rather than fibrillar collagen deposition - could mediate the local 18 increase in tissue stiffness. Taken together, myofibroblast density distinguished the 'EMT 19 niche' from the rest of the tumor bed, suggesting their central role in tumor invasion.

# 8. 3D cellular neighborhoods capture the tumor, myofibroblasts and macrophage crosstalk in the EMT niche

22 We therefore shifted our focus to the crosstalk between tumor cells, fibroblasts and

- 23 macrophages to investigate how the 'EMT niche' is formed and maintained. Through the
- 24 combination of 3D cellular neighborhoods and the sensitive detection of 165 ligands and 144
- 25 receptors via ISH (1-2 molecules/cell [14]), we quantified the spatial activity for 480 receptor-
- ligand pairs in 3D cellular neighborhoods (Fig 5e, Methods). In the CellChat database [42],
- 27 interactions enriched in the 'EMT niche' (Fig 5f) belonged either to the 'ECM-Receptor'
- 28 category, including FN1 (Fibronectin-1), THBS1 (Thrombospondin-1), THBS2
- 29 (Thrombospondin-2) and COL4A1 (Collagen type IV, alpha-1 chain), or were annotated as
- 30 'Secreted signaling', including SPP1 (Osteopontin) and IGF2 (Insulin-like growth factor-2).

1 Studying the directionality of these signaling networks in 3D neighborhoods, we confirmed 2 the role of macrophages as source of SPP1 signaling and identified fibroblasts and tumor cells 3 as main senders of 'ECM-receptor' and IGF2 interactions, respectively (Ext data fig5g, 4 orange dots). Strickingly, 'ECM-receptor' interactions were mainly received by tumor cells 5 and converged on multiple integrin receptors, including ITGA3, ITGAV and ITGB1 (Ext 6 data fig5g, blue dots). Integrins are the main cellular adhesion receptors and their central role 7 in tumor invasion is well-established. They represent key components of the cell migration machinery and their engagement activates intracellular pathways promoting survival, EMT 8 9 and invasion [43]. Accordingly, although individual signaling could be also found in other niches, the combination of SPP1, FN1, IGF2 and THBS2 spatial activity was collectively 10 11 restricted to the 'EMT niche' and distinguished it from the rest of the tumor bed (Fig 5g-i, 12 Ext data fig 5h-l). Interestingly, IGF signaling promoted myofibroblast differentiation of 13 lung fibroblasts grown on a soft substrate [44], [45]. Intriguingly, tumor-derived IGF2 may promote myofibroblast accumulation in the EMT niche, which further potentiates pro-14 15 invasive IGF signaling through IGFBPs and FN1 production. Furthermore, the co-localization of THBS2+ myofibroblasts and SPP1+ macrophages was recently linked with T-cell 16 17 exclusion in both lung [42] and colorectal tumors [46], linking the EMT niche with the

18 remodeling of the tumor immune microenvironment.

# **9. 3D** neighborhoods boost the quantification of immune niche-specific interactions,

# 20 including druggable immune checkpoints

- 21 Under the selective pressure of the immune system, tumor cells eventually develop strategies
- 22 to suppress anti-tumoral immune responses, including the reprogramming of antigen-
- 23 presenting cells (APCs, i.e. macrophages and dendritic cells). In turn, APCs may promote the
- 24 recruitment of regulatory T cells, further restricting the activation of tumor-specific cytotoxic
- 25 T cells [47]. Compatible with tumor immune escape, APC and regulatory T cells were co-
- 26 enriched in 'macrophage niches' and 'dendritic cell niches' (Fig 6a), while cytotoxic T cells -
- 27 despite their abundance- did not infiltrate the tumor bed and accumulated in 'T cell niches'
- 28 (Fig 6a,b).
- 29 To identify immunomodulatory interactions, we focused on interactions that distinguished
- 30 'dendritic cell niches' and 'macrophage niches' from the rest of the TME (Fig 6c).

1 Compatible with their role in immune cell recruitment (i.e. chemotaxis), numerous

- 2 chemokines were enriched in immune niches. The 3D spatial activity CCL19 (CC-chemokine
- 3 ligand 19), CCL21 and CXCL9 (C-X-C motif ligand 9), which regulate the homing of
- 4 dendritic and T cells in lymphoid tissues [48], marked location of 'dendritic cell niches' and
- 5 'T cell niches' in the TME (Fig 6e, Ext data fig 6b-c, Supp Video 2). In line with their
- 6 chemotactic role, CCL19 and CXCL9 interactions were received by most cell types in
- 7 'dendritic niches', with the exception of tumor cells (Ext data fig 6d), suggesting their
- 8 involvement in the induction of rather than their recruitment to 'dendritic niches'. Tumor
- 9 cells indeed acted as main MIF (Macrophage Inhibitory Factor) senders, a potent
- 10 chemoattractant upregulated in several tumors, including NSCLC [49]. MIF, whose spatial
- 11 activity was widespread in the tumor bed (**Ext data fig 6e**), promotes immunosuppressive
- 12 myeloid reprogramming and its inhibition decreased regulatory T cell and promoted cytotoxic
- 13 T cell infiltration in a melanoma lung metastasis model [50].
- 14 At the same time, LGALS9 (Galectin 9) and CD80 emerged as the ligands with the strongest
- 15 shared upregulation across all immune niches (**Fig 6f-g**), highlighting their importance in
- 16 regulating anti-tumoral immune responses. While the network of LGALS9 interactions in
- 17 'dendritic cell niches' involved all cell types, CD80 interactions mainly occurred between
- 18 dendritic cells and CTLA-4+ (Cytotoxic T-Lymphocyte Antigen 4) regulatory T cells. While
- 19 LGALS9-CD44 interactions promote the persistence and function of regulatory T cells in the
- 20 TME [51], CTLA4-CD80 interactions mediate their immunosuppressive function [52]. In
- 21 fact, CTLA4 prevents the interaction of CD80 with the co-stimulatory receptor CD28 on
- 22 cytotoxic T cell [53] and promotes the expression of IDO (indoleamine-2,3-dioxygenase) by
- 23 dendritic cells, which deprives adjacent T cells of tryptophan and further inhibits their
- 24 activation [54]. Confirming the functional activity of the CD80-CTLA4 axis, dendritic cells
- 25 engaged in CD80-CTLA4 interactions upregulated the expression of IDO1 (Ext data fig6f).
- 26 Remarkably, 3D neighborhoods consistently returned higher fold changes compared to their
- 27 2D counterparts, thereby boosting the identification of enriched ligands across all immune
- 28 niches (Fig 6d, Ext data fig 6a).
- 29 Taken together, 3D neighborhoods identified signaling networks spatially linked with tumor
- 30 invasion and immune responses and may provide the molecular rationale for their therapeutic
- 31 blockade, especially in the era of personalized medicine and mechanism-based combination

1 therapies [55]. Importantly, monoclonal antibodies targeting key receptors, such as anti-

- 2 CTLA4 or anti-VEGF agents, are already approved for the treatment of NSCLC, while
- 3 numerous inhibitors blocking IGF receptors, integrin signaling, or IDO enzymatic activity are
- 4 currently being evaluated in clinical trials (**Fig 6h**).

#### 5 **DISCUSSION**

This study represents the proof-of-principle for the molecular reconstruction of 3D cellular 6 7 neighborhoods combining high-plex, single-cell resolved spatial transcriptomic data with 8 imaging readout of tissue biomechanical properties. 3D neighborhoods captured the tissue 9 organization of cell types in multicellular niches and enabled the exploration of niche-specific 10 molecular states. Furthermore, the spatial mapping of more than 450 receptor-ligand pairs in 11 3D cellular neighborhoods allowed the systematic and highly sensitive (1-2 molecules/cell 12 [14]) quantification of niche-specific multicellular crosstalk. Leveraging the close spatial 13 proximity of interacting cells in 3D, we focused on physically possible interactions, thereby 14 boosting the specificity of our approach. Finally, the alignment of sections profiled with 15 multiple modalities allowed the integrative analysis of tissue gene expression, ECM 16 composition and protein marker levels. For example, combining SHG with cellular 17 communication analysis was instrumental in interpreting how myofibroblasts - together with 18 macrophages- modulate pro-invasive integrin signaling on tumor cells in the EMT niche. 19 Furthermore, the integration of mechanical and molecular readouts revealed how fibroblast 20 states in the TME are linked with the cellular and ECM composition of their neighborhoods. 21 In general, given the profound impact of tissue biomechanics in shaping cellular molecular 22 states (and vice versa), we envision that the systematic integration of spatial mechanical and 23 molecular readouts will reveal novel insights into tissue functioning in health and disease 24 (e.g., shedding light on the intricate role of tumor-stromal interplay).

While bi-dimensional histology and spatial omics [56], [57] represent powerful methods for the description of tissue pathology and the discovery of physiological and pathological cellular interplay, our data argue that 3D neighborhoods improved the identification and characterization of tissue niches. In line with a recent colorectal cancer study [7], 3D neighborhoods captured the spatial continuity of seemingly disconnected 'T cell niches' in 2D. Furthermore, the study of 'dendritic cell niches', where local anti-tumoral immune responses are orchestrated at the tumor surface was only possible in 3D. Importantly, 3D

1 neighborhoods boosted the quantification of cell-cell interactions, which is central to 2 coordination of immune responses in health and disease states [58]. Here we defined 3D 3 neighborhoods using a 50 µm radius and a 30µm section-to-section gap. Future studies will 4 be required to identify both the most cost-effective gap maximizing 3D information while 5 minimizing repeated sampling of the same cells (average cell radius 10-20 micron) and which 6 neighborhood radius is most appropriate to capture short vs long-distance molecular 7 dependencies. Nevertheless, taken together, our data demonstrate the importance of 3D 8 neighborhoods for the study of immune niches in the TME.

9 Focusing on an early-stage, aggressive NSCLC tumor, we demonstrate the ability of 3D 10 neighborhoods to capture the molecular mechanisms linked with tumor invasion and immune escape. While a recent IMC study demonstrated how the TME spatial organization can 11 12 accurately predict survival in early-stage NSCLC patients [59], limited plexity prevented the 13 identification of personalized drug targets. In this study, 3D neighborhoods spatially linked 14 VEGF, IGF and integrin signaling with tumor invasion in the 'EMT niche' and highlighted 15 CTLA4 and IDO1 as key immunosuppressive molecules in the patient under study. These 16 could serve as biomarkers for the response to agents already approved for NSCLC therapy, 17 including anti-VEGF (e.g. bevacizumab) and anti-CTLA4 agents (e.g. ipilimumab) 18 monoclonal antibodies. Personalized biomarkers not only have a crucial role in increasing 19 therapeutic efficacy and limiting treatment-related costs and toxicities but are also urgently 20 needed for the clinical study of novel therapeutic approaches. For instance, the failure of anti-21 IGF agents - after decades of encouraging preclinical results [53] - is mainly attributed to 22 recruitment of unselected NSCLC cohorts in phase III clinical trials due to the lack of 23 predictive biomarkers [60]. Like the simultaneous identification of multiple druggable 24 mutations by NGS sequencing opened the door to combination therapies [19], we hypothesize 25 that the high-plex quantification of active molecular pathways will pave the way to effective, personalized combination therapies. In this regard, small molecule inhibitors blocking the 26 27 signal transduction pathways downstream of multiple receptors are particularly promising. 28 For example, the simultaneous inhibition of integrin signalling (via FAK inhibitors) and 29 VEGFR [61], [62] or IGFR receptors [62] could represent a particularly attractive therapeutic 30 strategy in the patient under study. Ultimately, interventional studies enrolling large patient 31 cohorts will be critical to assess the predictive ability and clinical benefit of the mechanism-32 based, personalized biomarkers we identified in this single-patient, observational study.

1 Furthermore, while here we demonstrate the ability of a large cancer-related panel to profile

- 2 ligand-receptor interactions in well-established signaling pathways, genome-wide assays will
- 3 ultimately be needed to unbiasedly profile cell-cell interactions and discover novel
- 4 mechanisms and therapeutic targets. At the same time, unbiased assays will enable the
- 5 simultaneous profiling of ligand, receptors and intracellular response genes, further increasing
- 6 the likelihood of identifying active signaling axes. While mRNA represents a sensitive,
- 7 antibody-independent readout for protein production, discrepancies between transcripts and
- 8 protein levels do exist. Therefore, the systematic understanding of the molecular architecture
- 9 of the TME will likely require the simultaneous profiling of proteins and transcripts in single
- 10 cells. Finally, the integration of additional data modalities, such as epigenomics or
- 11 metabolomics, will provide an even more complete picture.
- 12

Acknowledgements: We thank Enes Senel, Marvin Jens, Leon Strenger, Kamil Lisek, Lieke
van de Haar, Marie Schott, Cledi Alicia Cerda Jara, all other members of the Rajewsky lab for
critical and useful discussions. Alexandra Tschernycheff, Veronica Jakobi and Margareta
Herzog for the lab organizational support. We thank Anca Margineanu of the Advanced Light
Microscopy Technology Platform at the Max-Delbrück-Center for her technical support with
two-photon microscopy. A special thanks to Gaetano Gargiulo for reviewing the manuscript.
N.R. and T.M.P. thank Nir Friedman for discussions and Stan Gorski for editorial feedback.

20 Illustrations in Figures 1a and 6h and Extended data figure 1a were created with Biorender.

21 Author Contributions: Conceptualization and design - T.M.P., I.L., N.K. and N.R.

- 22 Methodology T.M.P., N.K. Sample collection and pathology analysis S. S. Deep learning
- HE image analysis S.S., L.R., G.D. Sample processing and quality control G. T., A. B.
- 24 Spatial transcriptomics data collection and preprocessing Y. K., S. K., S. M., M. G. Second
- 25 harmonic imaging data collection and preprocessing A.W. Immunofluorescence data
- 26 collection and preprocessing D. L.-P., S. F., J. N., P.J. Computational analysis T.M.P.,
- 27 N.K. 3D renderings: D. L.-P. Writing Original Draft: T.M.P. Writing Review & Editing:
- 28 T.M.P. and N.R. with input from I.T., I.L., M.C., S.P., F.C., N. K. and F., K. All Authors
- 29 discussed and analyzed the data.

- 1 **Funding**: T.M.P. is financially supported by the Berlin School of Integrative Oncology
- 2 through the GSSP program of the German Academy of Exchange Service (DAAD) and by the
- 3 Add-on Fellowship of the Joachim Herz Foundation. S.P. is supported by Fondazione AIRC
- 4 under '5 per mille 2019 ID. 22759' programme and 'Fondazione AIRC, IG 2019 ID. 23307
- 5 project', the ERC programme CHARTAGING. S.P. and M.C. are supported by Fondazione
- 6 AIRC, IG 2022 ID. 27883 project. F.C., J.N. and S.F. acknowledge support by the Federal
- 7 Ministry of Education and Research (BMBF), as part of the National Research Initiatives for
- 8 Mass Spectrometry in Systems Medicine, under grant agreement no. 161L0222. N.R. thanks:
- 9 the Deutsche Forschungsgemeinschaft (DFG) grant number RA 838/5-1, Deutsches Zentrum
- 10 für Herz-Kreislauf-Forschung (DZHK) grant numbers 81Z0100105 and 81X2100155, the
- 11 Chan Zuckerberg Foundation (CZI)/Seed Network and NeuroCure/Cluster of Excellenz in the
- 12 neurosciences at the Charité Universitätsmedizin Berlin.
- 13 Competing interest: S.S. is an advisor for Aignostics. L.R. and G.D. are currently Aignostics
- 14 employees. S.M, M.G, and Y.L. are current employees and shareholders of NanoString
- 15 Technologies. F.K. is co-founder and advisor for Aignostics. The other authors declare that
- 16 they have no competing interests.

#### 1 MATERIALS AND METHODS

### 2 Study design

- 3 To study three-dimensional (3D) cellular neighborhoods in the tumor microenvironment
- 4 (TME), we focused on a formalin-fixed, paraffin-embedded (FFPE) tumor block from a
- 5 NSCLC patient and collected 34 5 µm-thick consecutive sections using a microtome. We
- 6 processed sections 4, 10, 16, 22, 28 and 34 with CosMx (section-to-section distance 30  $\mu$ m) to
- 7 generate high-plex, single-cell resolved spatial transcriptomics data, section 3 with both
- 8 second harmonic imaging (SHG) to study extracellular matrix (ECM) composition and
- 9 hematoxylin and eosin (H&E) staining to capture tissue morphology and section 12 with
- 10 immunofluorescence (IF) to validate tumor epithelial-to-mesenchymal transition (EMT) at the
- 11 protein level. We then employed computational methods for the 3D alignment of the analyzed
- 12 sections to generate a 3D multimodal atlas of NSCLC at single cell resolution.

#### 13 NSCLC patient's characteristics

- 14 The patient was a 63-year-old female, who presented with a pulmonary tumor mass in the
- 15 apex of the right upper lobe (RUL) in the positron emission tomography in March 2020.
- 16 Regarding smoking status, she was a 40 pack-year ex-smoker. The patient was fully active,
- 17 without any physical restrictions (ECOG grade 0). A transbronchial lung biopsy revealed a
- 18 TTF1-positive lung adenocarcinoma (LUAD) with acinar morphology. Staging workup by
- 19 abdominal and a brain CT-scan showed no other potential lesions, additionally the bone
- 20 scintigraphy was negative. Two months after initial diagnosis, a resection of the RUL was
- 21 performed. The pathological examination revealed a tumor with a maximum diameter of 23
- 22 mm, infiltration of the visceral pleura, lymphovascular invasion, and three metastases into
- hilar lymph nodes with a maximum diameter of 7 mm. The tumor was completely resected.
- 24 The pathological tumor classification was as follows: pT2a pN1 (3/24) L1 V0 Pn0 G2 R0.
- 25 The patient received three cycles of an adjuvant-combined chemotherapy (Cisplatin +
- 26 Vinorelbine).
- 27 In February 2021, the patient started having neuronal symptoms and a magnetic resonance
- 28 tomography of the head was performed revealing a 10 mm tumor in the frontal cortex. The
- 29 tumor was resected and a metastasis of the LUAD was histologically confirmed. Afterwards
- 30 the patient received cranial radiotherapy in the form of a volumetric intensity modulated arc

1 therapy (VMAT) at a dosage of 25,6 Gray (Gy). In August 2021 a second metastasis was

2 diagnosed in the left upper lobe (LUL) of the lung.

### 3 Sample collection and histological examination

Resected specimens and core needle biopsies were fixed in 10% buffered formalin before 4 5 gross processing. After overnight fixation, the specimens were cut in 5-mm-thick slices. As a 6 first step, the tumor was detected, described and the tumor diameter as well as the minimum 7 distances to the visceral pleura and the resection margins of lung parenchyma and bronchus 8 were measured. Next, the resection margins and the representative tumor parts showing the 9 relation to the relevant anatomical structures, described above, were embedded. Furthermore, 10 we retrieved all macroscopic detectable lymph nodes. Subsequently the tissue or biopsies were embedded in paraffin and were stored at room temperature at the archive of the Institute 11 12 of Pathology at the Charité University Hospital, Campus Mitte. Histological examination, 13 including diagnosis, tumor grading, pTNM-classification, angioinvasion, lymphatic invasion, 14 and tumor stage was done according to the 8th edition of the TNM classification (AJCC). The 15 study was performed according to the ethical principles for medical research of the 16 Declaration of Helsinki and approval was approved by the Ethics Committee of the Charité

17 University Medical Department in Berlin (EA4/243/21).

# 18 Deep learning segmentation of whole slide H&E images

19 For learning a tissue segmentation model, we collected around ~5,000 representative

20 pathologist annotations for 4 morphological sub-categories on H&E tissue morphology:

21 "Carcinoma", "Stroma", "Necrosis", and "Normal lung" (e.g. including "Alveoli",

22 "Capillaries", "Respiratory epithelium", "Vessels", etc.) for model training. For the

23 segmentation model, we used a U-Net [63] architecture with a ResNet101 backbone [64]. We

trained models over various hyperparameters for 50 epochs using the Adam optimizer [65]

and selected the top five models based on the global F1 performance on a validation set. We

then combined these five models into a mean ensemble, which achieved a global F1

27 performance of ~0.93 on a hold-out test set.

# 28 Quantification of RNA fragmentation

29 To quantify the extent of RNA fragmentation, we collected 3 10  $\mu$ m sections using a

30 Microtome (Leica Byostems). We then extracted RNA using Qiagen RNAse FFPE kit

- 1 according to manufacturer instructions and evaluated the percentage of total RNA fragments
- 2 longer than 200 nucleotides (DV200) using the TapeStation (Agilent). Compatible with
- 3 formalin fixation and prolonged storage at room temperature, the DV200 score was 60%.

# CosMx sample processing, staining, imaging, and cell segmentation for 1000-plex RNA profiling

6 CosMx sample processing, staining, imaging, and cell segmentation were performed as 7 previously described [14]. Briefly, tissue sections were placed to VWR Superfrost Plus Micro 8 Slide (Cat# 48311-703) for optimal adherence. Slides were then dried at 37°C overnight, 9 followed by deparaffinization, antigen retrieval and proteinase mediated permeabilization 10 (https://nanostring.com/products/cosmx-spatial-molecular-imager/single-cell-imagingoverview/). 1 nM RNA-ISH probes were applied for hybridization at 37°C overnight. After 11 12 stringent wash, a flow cell was assembled on top of the slide and cyclic RNA readout on 13 CosMx was performed (16-digit encoding strategy). After all cycles were completed, 14 additional visualization markers for morphology and cell segmentation were added including 15 pan-cytokeratin, CD45, CD3, CD298/B2M, and DAPI. Twenty-four 0.985mm × 0.657mm 16 fields of view (FOVs) were selected for data collection in each slice. The CosMx optical 17 system has an epifluorescent configuration based on a customized water objective (13×, NA 18 0.82), and uses widefield illumination, with a mix of lasers and light-emitting diodes (385 nm, 19 488 nm, 530 nm, 590 nm, 647 nm) that allow imaging of DAPI, Alexa Fluor-488, Atto-532, 20 Dyomics Dy-605 and Alexa Fluor-647, as well as removal of photocleavable dye components. The camera was a FLIR BFS-U3\_200S6M-C based on the IMX183 Sony 21 22 industrial CMOS sensor (pixel size 180nm). A 3D multichannel image stack (9 frames) was 23 obtained at each FOV location, with the step size of 0.8 µm. Registration, feature extraction, 24 localization, decoding of the presence of individual transcripts, and deep-learning based cell 25 segmentation (developed upon Cellpose [66]) were performed as previously described [14]. 26 The final segmentation mapped each transcript in the registered images to the corresponding 27 cell, as well as to subcellular compartments (nuclei, cytoplasm, membrane), where the 28 transcript is located.

# 29 Transcriptomic clustering of segmented cells

30 For downstream analyses we used the package Seurat [67] (v4.0.4) in R (v4.1, <u>https://www.R-</u>

31 project.org/). For each section, we imported 3 matrices containing the gene expression,

metadata and positions of segmented cells. We removed the negative probes from the gene
 expression matrix, defined a unique cell name and created a merged Seurat object with data
 from all the sections.

4 To identify cell types present in the tumor microenvironment, we adopted a very conservative

5 filtering strategy removing only cells with less than 10 detected genes and removing genes

6 detected in less than 1 cell. We then computed SCT-normalized and scaled gene expression

7 counts [68] and computed the 50 most variable principal components (PCs). We selected the

8 first 30 PCs to create a shared nearest neighbor graph and to compute a two-dimensional
9 UMAP plot [69] used for data visualization in a low dimensional space. Finally, we

10 partitioned the shared nearest neighbor graph using a resolution of 0.8 and identified 24

11 transcriptomic clusters.

#### 12 Cell type annotation of transcriptomic clusters

13 To annotate cell types present in the tumor microenvironment, we identified marker genes

14 enriched in each cluster for knowledge-based cell type annotation. Epithelial clusters,

15 characterized by positivity to panCK immunofluorescent staining, comprised both tumor cells

16 (EPCAM+ S100A10+) and non-malignant epithelial cells, including respiratory epithelium

17 (SCGB3A1+), basal epithelial cells (KRT5+) and alveolar cells (FGG+). We also detected

18 numerous stromal populations, including fibroblasts (COL1A2+), vascular (PECAM1+) and

19 lymphatic (*FABP5*+) endothelial cells, pericytes (*PDGFRB*+) and smooth muscle cells

20 (TAGLN+). We identified innate and adaptive immune cell populations, including

21 macrophages (CD68+), monocytes (LYZ+), dendritic cells (LAMP3+), mast cells (KIT+),

22 cytotoxic (*CD8A*+) and regulatory (*FOXP3*+) T cells, B cells (*IGHM*+), plasma cells

23 (CD79A+) and cycling immune cells (MKI67+). Finally, we merged clusters with similar

24 marker gene expression as probably related to different cellular states of the same cell type.

25 We thus annotated clusters '0' and '1' as fibroblasts, clusters '2' and '7' as macrophages and

26 clusters '4', '5', '20', '22' and '23' as tumor cells.

#### 27 Data integration with reference atlases

28 To compare gene expression profiles with published reference atlases, we performed label

29 transfer using the standard Seurat pipeline. We integrated our data with the Human Lung Cell

30 Atlas [21] to annotate lung resident cell types and with a NSCLC single cell cohort [22] to

#### 1 annotate tumor-specific cell types. For each reference dataset, we identified a subset of 900

- 2 shared 'features' (i.e. genes) using the SelectIntegrationFeatures function (nfeatures = 900)
- 3 and pairs of 'anchors' (i.e. cells) between the reference and our query dataset using the
- 4 FindTransferAnchors function (normalization.method = "SCT", reference.assay = 'SCT',
- 5 query.assay = 'SCT', reduction = 'pcaproject', dims = 1:20, features = features, nn.method=
- 6 'rann', eps = 0.5). Then, we leveraged the TransferData function (anchorset = anchors,
- 7 prediction.assay = TRUE, weight.reduction = 'pcaproject', dims = 1:20, eps = 0.5) to score
- 8 each cell in our query dataset for similarity with annotated cell types in the reference dataset.

# 9 3D alignment of spatial transcriptomic data

10 To align high-plex, single-cell resolved spatial transcriptomic data from 6 sequential, non-

- 11 consecutive sections, we leveraged the Spatial Transcriptomics ImgLib2/Imaging Project
- 12 (STIM) [23]. With STIM, we first converted our spatial transcriptomics data to the n5 image
- 13 format for efficient storage and processing using the 'st-resave' function. In doing so, we
- 14 assigned a channel to each gene and modeled gene expression values as pixel intensities at the
- 15 center of the segmentation mask. Then, we applied the 'st-align-pairs' function to align each
- 16 section to the one above and below (r=1) using the Scale Invariant Feature Transform (SIFT)
- 17 [70] according to the expression of the 15 genes with highest standard deviation (n=15).
- 18 Finally, we applied the 'st-align-global' function to identify a global optimum that minimizes
- 19 the distances between all corresponding points across all pairs of slices (--absoluteThreshold
- 20 100 --sf 0.5 --lambda 0.5 --skipICP).

#### 21 Identification of 2D and 3D cellular neighborhoods

- 22 Cellular neighborhoods in 2D and 3D were computed with a custom Python script as follows.
- 23 First, for a given cell, the Euclidean distances in 2 or 3D between that cell and all other cells
- 24 in the dataset were computed. This set of distances was then filtered to remove distances
- 25 greater than  $r = 50 \mu m$ , resulting in a list of neighboring cells for that given cell. This list was
- 26 finally used to construct the 2D and 3D neighborhood matrices by counting the number of
- 27 cells for each of the 18 cell types present in each cellular neighborhood.

#### 28 **3D** visualization of airways and **3D** cellular neighborhoods

- 29 To generate 3D plots at single cell-resolution, we leveraged the Giotto R package (v1.1.2)
- 30 [71] and the Plotly R package (v4.10.1, <u>https://plotly-r.com</u>). Briefly, we first created a Giotto

1 object with the 3D cell centers coordinates and cell type annotations. To visualize airways, we

- 2 used the 'spatPlot3D' function (a wrapper for Plotly 3D scatter plot) highlighting 'respiratory
- 3 epithelium' cells in green and showing all other cell types in gray. To visualize 3D cellular
- 4 neighborhoods, we selected an exemplary center cell (Section 22, FOV 1, Segmentation ID
- 5 132) and plotted neighboring cells within a 100  $\mu$ m center-to-center distance. We then
- 6 generated a 3D scatter plot using Plotly, highlighting the center cell in red, coloring the cells
- 7 within a 50 µm according to their cell type and showing the cells outside of the 3D
- 8 neighborhood (between 50 and 100  $\mu$ m) in gray.

# 9 Identification and annotation of 2D and 3D multicellular niches

10 To identify 2D/3D multicellular niches in the tumor microenvironment, we imported the 2D/3D neighborhood matrix as a new assay in Seurat. We excluded cells with incomplete 3D 11 12 neighborhoods, namely those located in sections 4 and 34 and those within 50µm from the 13 edges of sections 6, 12, 18 and 24. We then performed UMAP dimensionality reduction and 14 clustering (resolution = 0.3). 3D neighborhoods analysis returned 13 clusters (Supp Fig 1a). Furthermore, we merged clusters '3', '10' and '12' as 'T cell niches' and clusters '5' and '9' 15 16 as 'airways' given their shared neighborhood composition and spatial patterns (Supp Fig 1bc). In this way, we identified a total of 10 unique 3D niches, which we annotated based on the 17 average cell type counts per 3D neighborhood: 'tumor core' (Tumor cellshigh, Fibroblastslow, 18 Macrophages<sup>low</sup>), 'tumor surface' (Tumor cells<sup>high</sup>, Fibroblasts<sup>mid</sup>, Macrophages<sup>mid</sup>, Cytotoxic 19 T cells<sup>low</sup>), 'airways' (Respiratory epithelium<sup>high</sup>, Basal epithelial cells<sup>high</sup>), 'alveoli' (Alveolar 20 cellshigh), 'desmoplastic stroma' (Fibroblastshigh, Plasma cellslow), 'vascular stroma' 21 (Fibroblasts<sup>mid</sup>, Vascular endothelium<sup>mid</sup>, Pericytes<sup>mid</sup>), 'smooth muscle' (Smooth muscle 22 cellshigh), 'Macrophage niche' (Macrophageshigh, Tumor cellsmid), 'Dendritic cell niche' 23 (Dendritic cells<sup>high</sup>, Tumor cells<sup>mid</sup>, Macrophages<sup>mid</sup>, Cytotoxic T cells<sup>mid</sup>, Regulatory T 24 25 cells<sup>low</sup>) and 'T cell niche' (Cytotoxic T cells<sup>high</sup>). At the same time, 2D neighborhoods analysis returned 15 clusters (Supp Fig 1d). Similarly, we merged clusters '8', '10' and '13' 26 as 'tumor core', clusters '2' and '3' as 'tumor surface', clusters '5' and '12' as 'airways' and 27 clusters '4' and '14' as 'T cell niches' and identified 10 multicellular niches (Supp Fig 1e), 28 29 which overlapped with 3D ones, with the exception of 'dendritic cell niches' identified only in 3D and 'macrophage-rich stroma' (Fibroblasts<sup>mid</sup>, Macrophages<sup>mid</sup>) identified only in 2D. 30

31 **Tumor pseudotime analysis** 

1 To reconstruct their molecular dynamics, we ordered tumor cells according to their

2 pseudotime. We first generated a Seurat object including only tumor cells using the subset

- 3 function and then re-normalized gene expression counts using SCTransform. We then
- 4 selected the top 400 variable genes and grouped them in 5 PCs using the RunPCA function
- 5 for downstream analyses. These included UMAP embedding using the RunUMAP function
- 6 and pseudotime analysis. For the latter, we converted the Seurat object into
- 7 SingleCellExperiment format using the R package SingleCellExperiment (v1.16.0) [72] and
- 8 then used the slingshot function of the R package slingshot (v2.2.1) [73] to compute tumor
- 9 cell pseudotime. Finally, we converted pseudotime scores to ranks (between 0 and 1) and
- 10 added them as metadata in the Seurat object for plotting.

### 11 Immunofluorescence (IF) imaging

- 12 The IF workflow for FFPE tissues was performed as previously described [74]. In detail,
- 13 FFPE tissue was deparaffinized, rehydrated and a two-step antigen retrieval was performed at
- 14 pH 6 and pH 9 sequentially with a rinsing step in PBS in between. Slides were blocked in
- 15 Odyssey blocking buffer (LI-COR BioScience, Cat # 927-70001) for 30 minutes. Prior to
- 16 antibody incubation, a pre-bleaching step was performed in 4.5% H<sub>2</sub>O<sub>2</sub> and 24 mM NaOH
- 17 diluted in PBS for 30 minutes at room temperature in the presence of white light. The tissue
- 18 was counterstained with Hoechst 33342 (Thermo Fisher Scientific, Cat #62249), mounted
- 19 with ProLong<sup>™</sup> Diamond (Thermo Fisher Scientific, Cat #P36961) and imaged. After
- 20 acquisition, slides were soaked in PBS for 5-10 minutes to remove the coverslip and antibody
- 21 incubation was performed in a humid chamber at 4 °C overnight. Slides were then washed,
- 22 mounted, imaged and bleached. Images were acquired on a Zeiss Axioscan7 Slide scanner
- 23 using an EC Plan-Neofluor 20x/0.5 M27 objective with 1x1 binning.

#### 24 Antibodies

Antibody target protein	Vendor	Catalog no.	Clone	Fluorophore	Research resource identifier
E-cadherin	CST	3199	24E10	Alexa Fluor® 488	AB_10691457

Pan- Cytokeratin	Thermo Fisher Scientific	41- 9003-80	AE1/AE3	eFluor <sup>™</sup> 570	AB_11218704

# 1 Preprocessing of imaging data

2 To stitch and register the .czi image files, acquired on the Zeiss Axioscan7 widefield

3 microscope, the ASHLAR algorithm (v 1.17.0) [75] was used. To correct the tissue

4 autofluorescent background signal, we performed background subtraction. Images were

5 acquired before the first round of antibody staining; using the same settings for each channel

6 (only exposure time was modified). The software package from

7 github.com/SchapiroLabor/Background\_subtraction was used (v 0.3.3) based on the

8 following formula:

9  $Marker_{corrected} = Marker_{raw} - Background * \frac{Marker exposure time}{Background exposure time}$ 

# 10 Registration of IF and CosMx images

11 The IF multi-channel image stack from Section 12 was registered to the CosMx images of 12 Section 10. To do this, the IF data stored as pyramidal OME-TIFF images were cropped into a 13 rectangular region of interest (ROI) using bftools from Bio-Formats (v6.11.1) [76]. This was 14 done to exclude parts of the tissue outside CosMx ROI, reducing the overall size of the 15 images and simplifying the registration process. The 24 contiguous fields of view of CosMx 16 raw imaging data for Section 10 were then stitched into a single image using the 17 Grid/Collection stitching v1.2 plugin in Fiji v1.53t [77]. The average z-stack projection of the 18 stitched stack was exported as a pyramidal OME-TIFF image. Rigid and affine registration 19 was performed using wsireg 0.3.7 with default parameters, with the full IF stack of Section 12 20 as the moving image, and the stitched CosMx stack of Section 10 as the fixed (target) image.

# 21 Survival analysis

22 We downloaded the expression matrices and the associated clinical metadata of the LUAD

23 study directly from the TCGA cohort ( https://www.cancer.gov/about-

24 nci/organization/ccg/research/structural-genomics/tcga). We subsetted the cohort to remove

25 patients that received prior treatment, as well as donors for whom only data from healthy

1 tissue was available (control group). The corresponding bulk RNA expression data for these 2 patients was then obtained, and the FPKM values were log-transformed for further analyses. 3 To perform censored survival analysis, we considered the "days to last follow up" to be 4 equivalent to the "days to death", for the cases where the donor was still alive. To compute 5 gene enrichment scores, we used the R package GSVA v.1.46.0 with the method "zscore" and 6 a threshold of 0 to cluster the donors into low/high expression scores. The survival curve was 7 computed with the functions "Surv" and "survfit" of the R package survival v.3.4.0, and by considering the "days to last follow up" or "days to death" as time, the vital status (alive vs 8 9 dead) as the event, and stratifying the data by the clusters identified by the gene enrichment analysis as described above. To compute the hazard ratio, we computed a Cox model using 10 11 the function coxph of the R package survival and inserted the result into the function 12 tbl regression of the R package gtsummary v.1.7.0.

# 13 Second Harmonic Imaging

- 14 Label free imaging of collagen and elastin was performed on a Zeiss LSM 880 NLO equipped
- 15 with a Plan-Apochromat 10x NA 0.45 objective (Carl Zeiss Microscopy GmbH, Jena,
- 16 Germany) and a tunable femtosecond titanium-sapphire laser (Chameleon-Ultra II, Coherent,
- 17 Santa Clara, California). Using an excitation wavelength of 800 nm, the second-harmonic
- 18 generation signal from collagen was collected through a 395 405 nm spectral window on to
- 19 a GaAsP detector and autofluorescence emission from elastin was collected through a 435 -
- 20 480 nm spectral window on to a PMT.

# 21 ECM composition analysis

- 22 To quantify ECM levels of collagen and elastin in section 4 cellular neighborhoods, we first
- 23 imported cropped and aligned section 3 SHG TIFF images in R using the grDevices package
- 24 (v. 4.1.3). We then normalized the collagen and elastin channels by dividing the pixel
- 25 intensities by the maximum value in the respective channel. Finally, we quantified the mean
- 26 collagen and elastin pixel intensities in the square with side 2x 50 µm centered on the
- 27 segmentation center of each cell in section 4.

#### 28 Fibroblast transcriptomic clustering and annotation

29 To identify transcriptomic states of the fibroblast in the TME, we selected cells annotated as

30 fibroblasts with more than 100 detected transcripts for unsupervised clustering as described

- 1 above, this time selecting the first 5 PCs and identifying 6 clusters and a resolution= 0.15. We
- 2 then identified marker genes enriched in each cluster for literature-based cluster annotation
- 3 [78]–[82]: 'matrix fibroblasts' (LUM+ MGP+ TIMP1+), 'myofibroblasts' (FN1+ COL11A1+
- 4 ACTA2+), 'activated fibroblasts' (JUN+ FOS+ IGF1+), 'antigen-presenting' (CD74+ HLA-
- 5 *DRB1*+), '*CCL19*+ reticular' and '*CXCL10*+ reticular' fibroblasts.

### 6 Ligand spatial activity scores in 2D and 3D cellular neighborhoods

- 7 To estimate the spatial activity of a specific ligand, we first downloaded manually-curated,
- 8 literature-supported receptor ligand pairs from the CellChat Human database [42] and
- 9 selected those in which both the receptor and the ligand were present in our 960-gene panel.
- 10 For each center cell, we quantified the spatial activity of 164 ligands in its 2D and 3D cellular
- 11 neighborhoods. To quantify the activity of each ligand in a given cellular neighborhood, we
- 12 first evaluated single pairs of interacting cells comprising the center cell and one of its
- 13 neighbors. For each pair, we computed the geometric mean of receptor expression in the
- 14 center cell and ligand expression in the neighbor cell. In this way, we required the non-zero
- 15 expression of both receptor and ligand to have positive pair scores. We then compute the
- 16 overall ligand activity score for a specific cellular neighborhood summing all the pair scores
- 17 having the center cell as receiver. In the case of ligands paired with multiple receptors, we
- 18 summarized the ligand activity as the sum of the interactions with each of the associated
- 19 receptors.

#### 20 Niche enrichments

- 21 To identify the preferential localization of a group of cells g in a specific niche n, we
- 22 compared the observed and expected counts of g cells in niche n. The expected counts are
- 23 computed under the assumption of random, independent distribution of cells belonging to
- 24 group g and niche n. To compute expected counts, we simply multiplied the total abundance
- 25 of g cells in the TME and the fraction of niche n in the TME. We then compute the log2 fold
- changes as the log2 of the ratio between observed and expected counts. In this way, we
- 27 quantified the enrichment of infiltrating tumor cells, fibroblast states and cell types across all
- 28 3D niches.

#### 29 Quantification and visualization of 3D cellular density

- 1 We quantified the 3D spatial density of a group of cells g and visualized its 2D projection
- 2 using the geom\_density\_2d\_filled function from the ggplot2 package using alpha=0.5 and h=
- 3 5.6\*700. In this way, we quantified and visualized the 3D density of mesenchymal-like tumor
- 4 cells (defined as pseudotime rank > 0.75), vascular endothelium and pericytes, macrophages,
- 5 myofibroblasts and cytotoxic T cells.

#### 6 **3D** rendering of tissue niches, gene expression and ligand activity scores

7 Three-dimensional visualizations were generated by downscaling and mapping the spatial

- 8 coordinates of segmented cell centroids onto 300x300 images along the xy-axes, using data
- 9 from sections 10, 16, 22 and 28 along the z-axis. From these, 300x300x100 voxel data was
- 10 constructed by interpolating 25 intermediate sections between each of the four sections using
- 11 weighted Convolutional Wasserstein barycenters [83]. Voxel data were exported as TIFF files
- 12 and visualized using ParaView v5.10 as surface or volumetric representations.

#### 13 Statistical methods

- 14 Cluster-specific marker genes used for cell type and fibroblast state annotation, niche-specific
- 15 differentially expressed genes in a specific cell type (including tumor cells, fibroblasts and
- 16 macrophages) and niche-enriched ligands (including EMT, macrophage, dendritic, and T cell
- 17 niches) were identified using a Wilcoxon Rank Sum Test comparing the expression of all
- 18 genes in the group of interest versus all the remaining cells as implemented in the
- 19 FindMarkers function in the Seraut R package (v. 4.0.4). p-values added to violin and
- 20 boxplots were computed through an unpaired t-test using the stat compare means function of
- 21 the ggpubr R package (v 0.6.0). Computed p values were adjusted using Bonferroni correction
- 22 for multiple testing.

#### 23 Data and code availability

- 24 Image-based spatial transcriptomics are deposited on Zenodo at the following DOI
- 25 10.5281/zenodo.7899173 under restricted access for reviewing purposes. Unless requested
- 26 otherwise during the review process, open access to raw and processed data will be granted
- 27 upon acceptance of the manuscript, together with the release of the full analysis code through
- 28 our GitHub page https://github.com/rajewsky-lab. Furthermore, it will be possible to interactively
- 29 explore the analyzed data through an interactive webpage.

### 1 **REFERENCES**

- [1] N. Y. Larsen *et al.*, "Cellular 3D-reconstruction and analysis in the human cerebral
  cortex using automatic serial sections," *Commun Biol*, vol. 4, no. 1, p. 1030, 2021, doi:
  10.1038/s42003-021-02548-6.
- A. L. Kiemen *et al.*, "CODA: quantitative 3D reconstruction of large tissues at cellular
  resolution," *Nat Methods*, vol. 19, no. 11, pp. 1490–1499, 2022, doi: 10.1038/s41592022-01650-9.
- 8 [3] G. Palla, D. S. Fischer, A. Regev, and F. J. Theis, "Spatial components of molecular
  9 tissue biology," *Nature Biotechnology 2022 40:3*, vol. 40, no. 3, pp. 308–318, Feb.
  10 2022, doi: 10.1038/s41587-021-01182-1.

[4] X. Wang *et al.*, "Three-dimensional intact-tissue sequencing of single-cell
 transcriptional states," *Science (1979)*, vol. 361, no. 6400, Jul. 2018, doi:
 10.1126/SCIENCE.AAT5691/SUPPL\_FILE/AAT5691\_WANG\_SM\_TABLE S2.XLSX.

- 15 [5] H. S. Bhatia *et al.*, "Spatial proteomics in three-dimensional intact specimens," *Cell*,
  vol. 185, no. 26, pp. 5040-5058.e19, Dec. 2022, doi: 10.1016/J.CELL.2022.11.021.
- L. Kuett *et al.*, "Three-dimensional imaging mass cytometry for highly multiplexed
  molecular and cellular mapping of tissues and the tumor microenvironment," *Nat Cancer*, vol. 3, no. 1, pp. 122–133, 2022, doi: 10.1038/s43018-021-00301-w.
- [7] J.-R. Lin *et al.*, "Multiplexed 3D atlas of state transitions and immune interaction in
  colorectal cancer," *Cell*, vol. 186, no. 2, pp. 363-381.e19, 2023, doi:
  https://doi.org/10.1016/j.cell.2022.12.028.
- [8] S. G. Rodriques *et al.*, "Slide-seq: A scalable technology for measuring genome-wide
  expression at high spatial resolution," *Science (1979)*, vol. 363, no. 6434, pp. 1463–
  1467, Mar. 2019, doi:
- 26 10.1126/SCIENCE.AAW1219/SUPPL\_FILE/AAW1219S1.MOV.

1 2 3	[9]	P. L. Ståhl <i>et al.</i> , "Visualization and analysis of gene expression in tissue sections by spatial transcriptomics," <i>Science (1979)</i> , vol. 353, no. 6294, pp. 78–82, Jul. 2016, doi: 10.1126/SCIENCE.AAF2403/SUPPL_FILE/AAF2403_STAHL_SM.PDF.
4 5	[10]	A. Chen <i>et al.</i> , "Spatiotemporal transcriptomic atlas of mouse organogenesis using DNA nanoball-patterned arrays," <i>Cell</i> , vol. 185, no. 10, pp. 1777-1792.e21, May 2022,
6		doi: 10.1016/j.cell.2022.04.003.
7	[11]	S. Vickovic et al., "Three-dimensional spatial transcriptomics uncovers cell type
8		localizations in the human rheumatoid arthritis synovium," Communications Biology
9		2022 5:1, vol. 5, no. 1, pp. 1–11, Feb. 2022, doi: 10.1038/s42003-022-03050-3.
10	[12]	M. Wang et al., "High-resolution 3D spatiotemporal transcriptomic maps of
11		developing Drosophila embryos and larvae," Dev Cell, vol. 57, no. 10, pp. 1271-
12		1283.e4, May 2022, doi: 10.1016/J.DEVCEL.2022.04.006.
13	[13]	K. H. Chen, A. N. Boettiger, J. R. Moffitt, S. Wang, and X. Zhuang, "Spatially
14		resolved, highly multiplexed RNA profiling in single cells," Science (1979), vol. 348,
15		no. 6233, Apr. 2015, doi: 10.1126/SCIENCE.AAA6090/SUPPL_FILE/CHEN-
16		SM.PDF.
17	[14]	S. He et al., "High-plex imaging of RNA and proteins at subcellular resolution in fixed
18		tissue by spatial molecular imaging," Nat Biotechnol, vol. 40, no. 12, pp. 1794–1806,
19		Dec. 2022, doi: 10.1038/S41587-022-01483-Z.
20	[15]	C. Robert, "A decade of immune-checkpoint inhibitors in cancer therapy," Nat
21		Commun, vol. 11, no. 1, p. 3801, 2020, doi: 10.1038/s41467-020-17670-y.
22	[16]	L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-Tieulent, and A. Jemal, "Global
23		cancer statistics, 2012.," CA Cancer J Clin, vol. 65, no. 2, pp. 87–108, Mar. 2015, doi:
24		10.3322/caac.21262.
25	[17]	E. B. Garon et al., "Pembrolizumab for the Treatment of Non-Small-Cell Lung
26		Cancer," New England Journal of Medicine, vol. 372, no. 21, pp. 2018–2028, 2015,
27		doi: 10.1056/NEJMoa1501824.

1 [18] J. R. Brahmer et al., "Management of immune-related adverse events in patients treated 2 with immune checkpoint inhibitor therapy: American society of clinical oncology 3 clinical practice guideline," Journal of Clinical Oncology, vol. 36, no. 17, pp. 1714-1768, Jun. 2018, doi: 10.1200/JCO.2017.77.6385. 4 5 M. Dietel and C. Sers, "Personalized medicine and development of targeted therapies: [19] 6 The upcoming challenge for diagnostic molecular pathology. A review," Virchows Arch, vol. 448, no. 6, pp. 744–755, Jun. 2006, doi: 10.1007/S00428-006-0189-2. 7 8 [20] J. Zhou, A. Kulasinghe, A. Bogseth, K. O'Byrne, C. Punyadeera, and I. Papautsky, 9 "Isolation of circulating tumor cells in non-small-cell-lung-cancer patients using a 10 multi-flow microfluidic channel," Microsystems & Nanoengineering 2019 5:1, vol. 5, no. 1, pp. 1-12, Feb. 2019, doi: 10.1038/s41378-019-0045-6. 11 12 K. J. Travaglini et al., "A molecular cell atlas of the human lung from single-cell RNA [21] 13 sequencing," Nature 2020 587:7835, vol. 587, no. 7835, pp. 619-625, Nov. 2020, doi: 10.1038/s41586-020-2922-4. 14 15 [22] N. Kim *et al.*, "Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma," Nature Communications 2020 16 17 11:1, vol. 11, no. 1, pp. 1–15, May 2020, doi: 10.1038/s41467-020-16164-1. 18 S. Preibisch, N. Karaiskos, and N. Rajewsky, "Image-based representation of massive [23] spatial transcriptomics datasets," *bioRxiv*, p. 2021.12.07.471629, Dec. 2021, doi: 19 20 10.1101/2021.12.07.471629. 21 C. Wittekind and M. Neid, "Cancer invasion and metastasis," Oncology, vol. 69 Suppl [24] 22 1, no. SUPPL. 1, pp. 14-16, 2005, doi: 10.1159/000086626. 23 J. P. Their, "Epithelial-mesenchymal transitions in tumour progression," Nature [25] 24 Reviews Cancer 2002 2:6, vol. 2, no. 6, pp. 442–454, 2002, doi: 10.1038/nrc822. 25 J. Yang et al., "Guidelines and definitions for research on epithelial-mesenchymal [26] 26 transition," Nature Reviews Molecular Cell Biology 2020 21:6, vol. 21, no. 6, pp. 341-27 352, Apr. 2020, doi: 10.1038/s41580-020-0237-9.

1	[27]	N. Rajewsky et al., "LifeTime and improving European healthcare through cell-based
2		interceptive medicine.," Nature, vol. 587, no. 7834, pp. 377-386, Nov. 2020, doi:
3		10.1038/s41586-020-2715-9.
4	[28]	Y. L. Hsu, C. Y. Wu, J. Y. Hung, Y. S. Lin, M. S. Huang, and P. L. Kuo, "Galectin-1
5		promotes lung cancer tumor metastasis by potentiating integrin $\alpha 6\beta 4$ and
6		Notch1/Jagged2 signaling pathway," Carcinogenesis, vol. 34, no. 6, pp. 1370–1381,
7		Jun. 2013, doi: 10.1093/CARCIN/BGT040.
8	[29]	PL. Kuo et al., "Lung cancer-derived galectin-1 mediates dendritic cell anergy
9		through inhibitor of DNA binding 3/IL-10 signaling pathway," J Immunol, vol. 186,
10		no. 3, pp. 1521–1530, Feb. 2011, doi: 10.4049/JIMMUNOL.1002940.
11	[30]	Y. Wang et al., "N-myc downstream regulated gene 1(NDRG1) promotes the stem-like
12		properties of lung cancer cells through stabilized c-Myc," Cancer Lett, vol. 401, pp.
13		53-62, Aug. 2017, doi: 10.1016/J.CANLET.2017.04.031.
14	[31]	J. I. Jones, A. Gockerman, W. H. Busby, C. Camacho-Hubner, and D. R. Clemmons,
15		"Extracellular matrix contains insulin-like growth factor binding protein-5: potentiation
16		of the effects of IGF-I.," Journal of Cell Biology, vol. 121, no. 3, pp. 679-687, May
17		1993, doi: 10.1083/JCB.121.3.679.
18	[32]	H. Hua, Q. Kong, J. Yin, J. Zhang, and Y. Jiang, "Insulin-like growth factor receptor
19		signaling in tumorigenesis and drug resistance: a challenge for cancer therapy", doi:
20		10.1186/s13045-020-00904-3.
21	[33]	V. Evdokimova et al., "IGFBP7 binds to the IGF-1 receptor and blocks its activation
22		by insulin-like growth factors," Sci Signal, vol. 5, no. 255, Dec. 2012, doi:
23		10.1126/SCISIGNAL.2003184.
24	[34]	R. Tamura, T. Tanaka, Y. Akasaki, Y. Murayama, K. Yoshida, and H. Sasaki, "The
25		role of vascular endothelial growth factor in the hypoxic and immunosuppressive
26		tumor microenvironment: perspectives for therapeutic implications," Med Oncol, vol.
27		37, no. 1, Jan. 2019, doi: 10.1007/S12032-019-1329-2.

1 [35] N. Mor-Vaknin, A. Punturieri, K. Sitwala, and D. M. Markovitz, "Vimentin is secreted 2 by activated macrophages," Nature Cell Biology 2002 5:1, vol. 5, no. 1, pp. 59-63, 3 Dec. 2002, doi: 10.1038/ncb898. 4 [36] E. M. Palmieri et al., "Pharmacologic or Genetic Targeting of Glutamine Synthetase 5 Skews Macrophages toward an M1-like Phenotype and Inhibits Tumor Metastasis," 6 Cell Rep, vol. 20, no. 7, pp. 1654–1666, Aug. 2017, doi: 10.1016/j.celrep.2017.07.054. 7 F. Shojaei et al., "Osteopontin induces growth of metastatic tumors in a preclinical [37] model of non-small lung cancer," J Exp Clin Cancer Res, vol. 31, no. 1, p. 26, 2012, 8 9 doi: 10.1186/1756-9966-31-26. 10 [38] Q. Zhang et al., "The spatial transcriptomic landscape of non-small cell lung cancer 11 brain metastasis," Nat Commun, vol. 13, no. 1, Dec. 2022, doi: 10.1038/S41467-022-12 33365-Y. 13 [39] T. Panciera et al., "Reprogramming normal cells into tumour precursors requires ECM 14 stiffness and oncogene-mediated changes of cell mechanical properties," Nature Materials 2020 19:7, vol. 19, no. 7, pp. 797-806, Feb. 2020, doi: 10.1038/s41563-020-15 16 0615-x. I. Acerbi et al., "Human breast cancer invasion and aggression correlates with ECM 17 [40] stiffening and immune cell infiltration," Integr Biol (Camb), vol. 7, no. 10, pp. 1120-18 1134, Oct. 2015, doi: 10.1039/C5IB00040H. 19 20 [41] G. Gabbiani, "The myofibroblast in wound healing and fibrocontractive diseases," J 21 Pathol, vol. 200, no. 4, pp. 500–503, Jul. 2003, doi: 10.1002/PATH.1427. 22 S. Jin et al., "Inference and analysis of cell-cell communication using CellChat," [42] 23 Nature Communications 2021 12:1, vol. 12, no. 1, pp. 1-20, Feb. 2021, doi: 24 10.1038/s41467-021-21246-9. 25 H. Hamidi and J. Ivaska, "Every step of the way: integrins in cancer progression and [43] 26 metastasis," Nature Reviews Cancer 2018 18:9, vol. 18, no. 9, pp. 533-548, Jul. 2018, 27 doi: 10.1038/s41568-018-0038-z.

1	[44]	C. F. Hung, M. G. Rohani, S. soon Lee, P. Chen, and L. M. Schnapp, "Role of IGF-1
2		pathway in lung fibroblast activation," Respir Res, vol. 14, no. 1, pp. 1-12, Oct. 2013,
3		doi: 10.1186/1465-9921-14-102/FIGURES/5.
4	[45]	J. A. Grout et al., "Spatial Positioning and Matrix Programs of Cancer-Associated
5		Fibroblasts Promote T-cell Exclusion in Human Lung Tumors," Cancer Discov, vol.
6		12, no. 11, pp. 2606–2625, Nov. 2022, doi: 10.1158/2159-8290.CD-21-1714.
7	[46]	J. Qi et al., "Single-cell and spatial analysis reveal interaction of FAP+ fibroblasts and
8		SPP1+ macrophages in colorectal cancer," Nature Communications 2022 13:1, vol. 13,
9		no. 1, pp. 1–20, Apr. 2022, doi: 10.1038/s41467-022-29366-6.
10	[47]	S. K. Wculek, F. J. Cueto, A. M. Mujal, I. Melero, M. F. Krummel, and D. Sancho,
11		"Dendritic cells in cancer immunology and immunotherapy," Nat Rev Immunol, vol.
12		20, no. 1, pp. 7–24, Jan. 2020, doi: 10.1038/S41577-019-0210-Z.
13	[48]	R. Förster, A. C. Davalos-Misslitz, and A. Rot, "CCR7 and its ligands: balancing
14		immunity and tolerance," Nat Rev Immunol, vol. 8, no. 5, pp. 362-371, May 2008, doi:
15		10.1038/NRI2297.
16	[49]	R. Mora Barthelmess, B. Stijlemans, and J. A. Van Ginderachter, "Hallmarks of
17		Cancer Affected by the MIF Cytokine Family," Cancers (Basel), vol. 15, no. 2, Jan.
18		2023, doi: 10.3390/CANCERS15020395.
19	[50]	C. R. Figueiredo et al., "Blockade of MIF-CD74 signalling on macrophages and
20		dendritic cells restores the antitumour immune response against metastatic melanoma,"
21		Front Immunol, vol. 9, no. MAY, p. 1132, May 2018, doi:
22		10.3389/FIMMU.2018.01132/BIBTEX.
23	[51]	C. Wu et al., "Galectin-9-CD44 interaction enhances stability and function of adaptive
24		regulatory T cells," Immunity, vol. 41, no. 2, p. 270, Aug. 2014, doi:
25		10.1016/J.IMMUNI.2014.06.011.
26	[52]	A. D. Waldman, J. M. Fritz, and M. J. Lenardo, "A guide to cancer immunotherapy:
27		from T cell basic science to clinical practice," Nature Reviews Immunology 2020
28		20:11, vol. 20, no. 11, pp. 651–668, May 2020, doi: 10.1038/s41577-020-0306-5.

1 2 3 4	[53]	P. S. Linsley, J. A. L. Greene, W. Brady, J. Bajorath, J. A. Ledbetter, and R. Peach, "Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors," <i>Immunity</i> , vol. 1, no. 9, pp. 793–801, 1994, doi: 10.1016/S1074-7613(94)80021-9
5	[ = 4]	M. Lie et al. "Transfire the IDO1 actions in some provident has her
5	[34]	M. Liu <i>et al.</i> , "Targeting the IDOT pathway in cancer: From bench to bedside," $J$
6 7		Y/TABLES/1.
8	[55]	A. C. Obenauf, "Mechanism-based combination therapies for metastatic cancer," Sci
9		Transl Med, vol. 14, no. 655, Jul. 2022, doi: 10.1126/SCITRANSLMED.ADD0887.
10	[56]	L. Keren et al., "A Structured Tumor-Immune Microenvironment in Triple Negative
11		Breast Cancer Revealed by Multiplexed Ion Beam Imaging," Cell, vol. 174, no. 6, pp.
12		1373-1387.e19, Sep. 2018, doi: 10.1016/J.CELL.2018.08.039.
13	[57]	C. Giesen et al., "Highly multiplexed imaging of tumor tissues with subcellular
14		resolution by mass cytometry," Nature Methods 2014 11:4, vol. 11, no. 4, pp. 417-422,
15		Mar. 2014, doi: 10.1038/nmeth.2869.
16	[58]	M. J. T. Stubbington, O. Rozenblatt-Rosen, A. Regev, and S. A. Teichmann, "Single-
17		cell transcriptomics to explore the immune system in health and disease," Science
18		(1979), vol. 358, no. 6359, pp. 58-63, Oct. 2017, doi:
19		10.1126/SCIENCE.AAN6828/ASSET/F50CA522-9704-48C5-83E4-
20		B0AF091F304C/ASSETS/GRAPHIC/358_58_F4.JPEG.
21	[59]	M. Sorin et al., "Single-cell spatial landscapes of the lung tumour immune
22		microenvironment," Nature 2023 614:7948, vol. 614, no. 7948, pp. 548-554, Feb.
23		2023, doi: 10.1038/s41586-022-05672-3.
24	[60]	M. Pollak, "The insulin and insulin-like growth factor receptor family in neoplasia: an
25		update," Nat Rev Cancer, vol. 12, no. 3, pp. 159–169, Mar. 2012, doi:
26		10.1038/NRC3215.

1	[61]	E. Kurenova et al., "The FAK scaffold inhibitor C4 disrupts FAK-VEGFR-3 signaling
2		and inhibits pancreatic cancer growth," Oncotarget, vol. 4, no. 10, pp. 1632-1646,
3		2013, doi: 10.18632/ONCOTARGET.1365.
4	[62]	N. Watanabe et al., "Dual tyrosine kinase inhibitor for focal adhesion kinase and
5		insulin-like growth factor-I receptor exhibits anticancer effect in esophageal
6		adenocarcinoma in vitro and in vivo," Clin Cancer Res, vol. 14, no. 14, pp. 4631-4639,
7		Jul. 2008, doi: 10.1158/1078-0432.CCR-07-4755.
8	[63]	W. Weng and X. Zhu, "U-Net: Convolutional Networks for Biomedical Image
9		Segmentation," IEEE Access, vol. 9, pp. 16591-16603, May 2015, doi:
10		10.48550/arxiv.1505.04597.
11	[64]	K. He, X. Zhang, S. Ren, and J. Sun, "Deep Residual Learning for Image
12		Recognition," Proceedings of the IEEE Computer Society Conference on Computer
13		Vision and Pattern Recognition, vol. 2016-December, pp. 770-778, Dec. 2015, doi:
14		10.48550/arxiv.1512.03385.
15	[65]	D. P. Kingma and J. L. Ba, "Adam: A Method for Stochastic Optimization," 3rd
16		International Conference on Learning Representations, ICLR 2015 - Conference Track
17		Proceedings, Dec. 2014, doi: 10.48550/arxiv.1412.6980.
18	[66]	C. Stringer, T. Wang, M. Michaelos, and M. Pachitariu, "Cellpose: a generalist
19		algorithm for cellular segmentation," Nat Methods, vol. 18, no. 1, pp. 100-106, Jan.
20		2021, doi: 10.1038/S41592-020-01018-X.
21	[67]	T. Stuart et al., "Comprehensive Integration of Single-Cell Data," Cell, vol. 177, no. 7,
22		pp. 1888-1902.e21, Jun. 2019, doi:
23		10.1016/J.CELL.2019.05.031/ATTACHMENT/2F8B9EBE-54E6-43EB-9EF2-
24		949B6BDA8BA2/MMC3.PDF.
25	[68]	C. Hafemeister and R. Satija, "Normalization and variance stabilization of single-cell
26		RNA-seq data using regularized negative binomial regression," Genome Biol, vol. 20,
27		no. 1, pp. 1–15, Dec. 2019, doi: 10.1186/S13059-019-1874-1/FIGURES/6.

1 [69] L. McInnes, J. Healy, N. Saul, and L. Großberger, "UMAP: Uniform Manifold 2 Approximation and Projection," J Open Source Softw, vol. 3, no. 29, p. 861, Sep. 2018, 3 doi: 10.21105/JOSS.00861. 4 [70] D. G. Lowe, "Object recognition from local scale-invariant features," Proceedings of 5 the IEEE International Conference on Computer Vision, vol. 2, pp. 1150–1157, 1999, 6 doi: 10.1109/ICCV.1999.790410. 7 R. Dries et al., "Giotto: a toolbox for integrative analysis and visualization of spatial [71] expression data," Genome Biol, vol. 22, no. 1, pp. 1-31, Dec. 2021, doi: 8 9 10.1186/S13059-021-02286-2/FIGURES/6. 10 R. A. Amezquita et al., "Orchestrating single-cell analysis with Bioconductor," Nature [72] 11 Methods 2019 17:2, vol. 17, no. 2, pp. 137-145, Dec. 2019, doi: 10.1038/s41592-019-12 0654-x. 13 [73] K. Street et al., "Slingshot: Cell lineage and pseudotime inference for single-cell 14 transcriptomics," BMC Genomics, vol. 19, no. 1, pp. 1-16, Jun. 2018, doi: 15 10.1186/S12864-018-4772-0/FIGURES/5. 16 J. Eng et al., "A framework for multiplex imaging optimization and reproducible [74] 17 analysis," Commun Biol, vol. 5, no. 1, Dec. 2022, doi: 10.1038/S42003-022-03368-Y. 18 J. L. Muhlich, Y.-A. Chen, C. Yapp, D. Russell, S. Santagata, and P. K. Sorger, [75] 19 "Stitching and registering highly multiplexed whole-slide images of tissues and tumors 20 using ASHLAR," Bioinformatics, vol. 38, no. 19, pp. 4613-4621, Sep. 2022, doi: 10.1093/BIOINFORMATICS/BTAC544. 21 22 M. Linkert et al., "Metadata matters: access to image data in the real world," Journal of [76] 23 Cell Biology, vol. 189, no. 5, pp. 777–782, May 2010, doi: 10.1083/JCB.201004104. 24 S. Preibisch, S. Saalfeld, and P. Tomancak, "Globally optimal stitching of tiled 3D [77] 25 microscopic image acquisitions," Bioinformatics, vol. 25, no. 11, pp. 1463-1465, Jun. 26 2009, doi: 10.1093/BIOINFORMATICS/BTP184.

1	[78]	Y. Kieffer et al., "Single-cell analysis reveals fibroblast clusters linked to
2		immunotherapy resistance in cancer," Cancer Discov, vol. 10, no. 9, pp. 1330-1351,
3		Sep. 2020, doi: 10.1158/2159-8290.CD-19-1384/333435/AM/SINGLE-CELL-
4		ANALYSIS-REVEALS-FIBROBLAST-CLUSTERS.
5	[79]	D. Lambrechts et al., "Phenotype molding of stromal cells in the lung tumor
6		microenvironment," Nat Med, vol. 24, no. 8, pp. 1277-1289, Aug. 2018, doi:
7		10.1038/S41591-018-0096-5.
8	[80]	E. Elyada et al., "Cross-Species Single-Cell Analysis of Pancreatic Ductal
9		Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts," Cancer
10		Discov, vol. 9, no. 8, pp. 1102–1123, Aug. 2019, doi: 10.1158/2159-8290.CD-19-0094.
11	[81]	A. L. Fletcher, S. E. Acton, and K. Knoblich, "Lymph node fibroblastic reticular cells
12		in health and disease," Nat Rev Immunol, vol. 15, no. 6, pp. 350-361, Jun. 2015, doi:
13		10.1038/NRI3846.
14	[82]	L. Cords et al., "A Cancer-Associated Fibroblast Classification Framework for Single-
15		Cell Data," bioRxiv, p. 2022.12.14.520398, Dec. 2022, doi:
16		10.1101/2022.12.14.520398.
17	[83]	J. Solomon et al., "Convolutional wasserstein distances," ACM Transactions on
18		Graphics (TOG), vol. 34, no. 4, Jul. 2015, doi: 10.1145/2766963.
10		

19

20



#### 2 Figure 1. Molecular histology of the tumor microenvironment at single cell resolution. a)

3 Experimental design for the 3D reconstruction of cellular neighborhoods. 34 consecutive 5

4 µm sections were cut from one non-small cell lung cancer (NSCLC) tumor block. Second

5 harmonic imaging (SHG, quantifies collagen and elastin), hematoxylin and eosin (H&E,

6 detects tissue morphology), spatial transcriptomics (1000-plex RNA in situ hybridization with

7 CosMx Spatial Molecular Imager), immunofluorescence (IF) were combined for multimodal

- 8 spatial profiling. **b**) Keratin 19 (KRT19) mRNA localization matches pan-cytokeratin
- 9 immunostaining. Left: *KRT19* mRN A captured by CosMx (green: *KRT19* transcripts, gray:
- 10 DAPI (nuclei), blue: cell segmentation masks). Right: pan-cytokeratin IF (epithelial cells,
- 11 green; DAPI: blue) c) UMAP of cell types in the tumor microenvironment. d) Traditional and

- 1 molecular histology. Top left and bottom right: H&E staining (section 3). Top right and
- 2 bottom left: Cell types mapped to their spatial position (section 4). e) Congruence of gene
- 3 expression profiles in segmented cells with healthy and tumor single cell RNA sequencing
- 4 references. UMAP plots are colored by their Label Transfer scores indicating similarity to
- 5 reference cell types.



1

Extended data figure 1 related to figure 1. a) Schematics of characteristics, staging and
clinical history of the NSCLC patient under study. We investigated the lobectomy sample. b)
Deep learning-based whole slide H&E annotation of carcinoma, stroma, and normal lung

- 1 regions. Black box: profiled region of interest (ROI). c) Whole slide images of the sections
- 2 profiled with CosMx. Yellow: 24 fields of view in each ROI. d) Correlation of gene
- 3 expression across sections. Section-to-section Pearson correlation of aggregate gene
- 4 expression profiles. e) UMAP plot of segmented cells. Cells are colored according to their
- 5 transcriptomic cluster assignment. f) Cluster expression of canonical markers used for cell
- 6 type annotations. g) Cell type distributions of pancytokeratin (panCK) immunofluorescence
- 7 signal (top), cell area from the segmentation masks (middle) and transcript counts (bottom).
- 8 h) Spatial plot of cell types in section 4. i) Tissue morphology by conventional hematoxylin
- 9 and eosin staining in section 3.



1

#### 2 Figure 2. 3D neighborhoods identify multicellular niches in the tumor

3 microenvironment. a) 3D plot of cells in the 6 CosMx sections after registration. Green: 4 respiratory epithelium cells, gray: other cell types. Axes are scaled to the same length. b) 5 Analysis of 3D cellular neighborhoods. Exemplary 3D neighborhood (left). Red: center cell: 6 red, dark green: tumor cells, orange: fibroblasts, gray: other cell types. Quantification of cell 7 types in 3D neighborhoods is used to build the neighborhood matrix (right). Tumor cells, 8 fibroblasts and macrophages are shown out of 18 cell types quantified. c) UMAP of 3D 9 cellular neighborhoods. Cells are grouped based on their 3D neighborhood composition, 10 regardless of their gene expression, and colored by 3D niche assignment. d) Composition of 11 3D neighborhoods in multicellular niches. Heatmap of niche-specific average cell type 3D neighborhood counts. Color scale is clipped to 30 for visualization purposes. e) Spatial map of 12 13 3D multicellular niches (section 10). Color legend in panel c. gray: cells within 50 µm of the 14 section edge. f) Comparison of 2D and 3D niches. Alluvial plot of niche assignments when

- 1 analyzing 2D and 3D neighborhoods. Lines follow the assignment of the same cell in 3D
- 2 (left) and 2D niches (left). Color legend in panel c, dark green: 'macrophage-rich stroma'. g)
- 3 3D neighborhoods capture niche spatial continuity. Cells assigned to 'T cell niches' and
- 4 'tumor core' only in 3D (highlighted) connect seemingly separated 2D niches.



2 Extended data figure 2 related to figure 2. a) Boxplot of cellular displacement following 3 3D alignment. The distribution of cellular shifts for each section is shown. Section 4 was used 4 as the anchoring section. b) Richness of 2D and 3D cellular neighborhoods. The distribution for the total number of neighbors, the number of different cell types and the alpha diversity 5 (Chao index) are shown for 2D and 3D neighborhoods. \*\*\*\*: t-test p-values < 0.005, n= 6 7 218,378. c) Violin plots of the number of neighbors (top) and different cell types per 3D 8 neighborhood for cells in different 3D niches. d) Pathologist manual annotation of tissue 9 domains superimposed to hematoxylin and eosin (section 3). e) Left: UMAP of 2D cellular 10 neighborhoods. Cells are grouped based on their 2D neighborhood composition and colored 11 by 2D niche assignment. Right: Spatial map of 2D multicellular niches (section 10), gray: 12 cells within 50  $\mu$ m of the section edge.



2 Figure 3. Tumor cells acquire pro-invasive molecular programs in the EMT niche. a) 3D 3 rendering of the tumor bed. b) 3D rendering of infiltrating tumor cells extending beyond the tumor surface. c) Molecular characterization of infiltrating tumor cells. Comparison of gene 4 5 expression between tumor cells located in the desmoplastic stroma vs those in the tumor core. 6 Red: genes with more > 5% expression difference, labeled: red genes with absolute fold 7 change > 1.33. d) Pseudotime captures tumor cell molecular dynamics. UMAP plot of tumor 8 cells based on their transcriptomic profiles. Tumor cells are colored by pseudotime rank. e) 9 Epithelial state marker CDH1 (E-Cadherin) is downregulated with increasing pseudotime. 10 UMAP plot of tumor cells colored by normalized CDH1 expression. f) Tumor cells undergo 11 epithelial-to-mesenchymal transition (EMT) in one EMT niche. 3D spatial density of tumor 12 cells with late pseudotime (rank >0.75) highlights one region of the tumor bed.

1





2 Extended data figure 3 related to figure 3. a) Tumor cells quantification across all niches. The left barplot includes all tumor cells (yellow: tumor core, red: tumor surface, gray: outside 3 4 the tumor bed), while the right one quantifies the niche assignments of infiltrating tumor cells. 5 Color legend in panel b. b) Preferential localization of infiltrating tumor cells in 3D niches. 6 log2 fold changes are computed from the ratio of the observed vs expected number of 7 infiltrating tumor cells per niche. c) Protein validation of keratin upregulation in infiltrating 8 tumor cells. Quantification of pan-cytokeratin (panCK) immunostaining intensity in tumor 9 cells located in the tumor core, surface and desmoplastic stroma. \*\*\*\*: t-test p-values < 10 0.005, n= 38,804. d) Molecular gradients at the tumor surface. Gene expression heatmap for the top differential genes between tumor cells in the tumor core and desmoplastic stroma. 11 12 Row-scaled average gene expression values for tumor cells in the tumor core, surface and 13 desmoplastic stroma. e-f) Epithelial to mesenchymal transition dynamics in tumor cells.

- 1 Tumor expression of (e) epithelial state marker *EPCAM* (Epithelial Cell Adhesion Molecule)
- 2 and (f) mesenchymal marker VIM (Vimentin). g) Pseudotime progressively increases moving
- 3 from the tumor core to the tumor surface and desmoplastic stroma. Boxplot of the pseudotime
- 4 rank distribution of tumor cells assigned to the tumor core, surface, and desmoplastic stroma.
- 5 \*\*\*\*: t-test p-values < 0.005, n= 38,804. h) Spatial distribution of tumor pseudotime scores. i)
- 6 Immunofluorescence validation of CDH1 downregulation in the EMT niche (section 12).
- 7 Left: Immunostaining for nuclei (DAPI: white) and tumor and normal epithelial cells (panCK:
- 8 green). Right: Immunostaining for nuclei (DAPI: white) and epithelial phenotype (CDH1:
- 9 magenta), white square: EMT niche.



1

2 Figure 4. A multicellular molecular signature links the EMT niche with reduced

survival in a large cohort. a) 3D rendering of EMT niche (yellow). b) EMT niche tumor
biomarkers. Differential gene expression between tumor cells located inside the EMT niche

5 vs those outside. Red: genes with more > 5% expression difference, labeled: red genes with

6 absolute fold change > 1.33. c) *LGALS1* expression is specific for tumor cells in the EMT

7 niche (3D surface rendering), black box: EMT niche. d) Tumor cells, fibroblasts and

- 8 macrophages are the main cell types in the EMT niche. Barplot of cell type composition
- 9 inside and outside the EMT niche. Gray: cell types with <4% abundance in both regions. e)
- 10 EMT niche fibroblast biomarkers. Differential gene expression between fibroblasts located
- 11 inside the EMT niche vs those outside. Red: genes with more > 5% expression difference,

- 1 labeled: red genes with absolute fold change > 1.33. f) VEGFA expression is specific for
- 2 fibroblasts in the EMT niche (3D volumetric rendering). Gray: tumor bed (3D surface
- 3 rendering), black box: EMT niche. g) EMT niche macrophage biomarkers. Differential gene
- 4 expression between macrophages located inside the EMT niche vs those outside. Red: genes
- 5 with more > 5% expression difference, labeled: red genes with absolute fold change > 1.33.
- 6 **h**) *SPP1* expression is specific for macrophages in the EMT niche (3D volumetric rendering).
- 7 Gray: tumor bed (3D surface rendering), black box: EMT niche. i) A multicellular EMT niche
- 8 molecular signature links the EMT niche with reduced survival. Survival plot of 503 lung
- 9 adenocarcinoma patients from The Cancer Genome Atlas (bulk RNA-seq) stratified into high
- 10 and low enrichment for the combined expression of LGALS1, NDRG1, IGFBP5, VEGA and
- 11 *SPP1*.



1

2 Extended data figure 4 related to figure 4. a) NDRG1 expression is specific for tumor cells 3 in the EMT niche (3D surface rendering), black box: EMT niche. b) Preferential localization 4 of cell types in the EMT niche. log2 fold changes are computed from the ratio between the 5 observed and expected number of cells per cell type in the EMT niche. c-e) 3D volumetric

- 1 rendering of IGFBP5 (c), IGFBP7 (d) and FN1 (e) fibroblast expression. Gray: tumor bed
- 2 (3D surface rendering), black box: EMT niche. f-g) 3D spatial density plot of vascular
- 3 endothelium and pericytes (f) and macrophages (g). h-n) Survival plot of 503 lung
- 4 adenocarcinoma patients from The Cancer Genome Atlas (bulk RNA-seq) stratified into high
- 5 and low enrichment for the individual expression of LGALS1 (h), NDRG1 (i), IGFBP5 (l),
- 6 *VEGA* (m) and *SPP1* (n).



#### 1

#### 2 Figure 5. Multimodal analysis of 3D neighborhoods captures the tumor, myofibroblasts 3 and macrophage crosstalk in the EMT niche. a) Extracellular matrix (ECM) remodeling in 4 the TME. Second harmonic (SHG) imaging (section 3), purple: elastin, green: fibrillar 5 collagen, white square: EMT niche. b) Collagen signal (section 3) in tumor cell 6 neighborhoods (section 4). Tumor cells colored by their mean collagen signal are plotted. 7 white square: EMT niche. c) Different fibroblast transcriptomic states in the TME. UMAP 8 plot of fibroblasts colored by cluster assignment. d) 3D spatial density plot of myofibroblasts, 9 demonstrating their accumulation in the EMT niche. e) 3D spatial analysis of cellular

- 10 interactions. The sensitive co-detection of ligands and its receptors in 3D cellular
- 11 neighborhoods is leveraged to quantify the 3D spatial activity scores. **f**) EMT niche-specific
- 12 ligands. Comparison of 3D spatial activity scores between cells located inside the EMT niche

- 1 vs those outside. Red: Ligands with more > 5% interaction difference, labeled: red genes with
- 2 absolute fold change > 1.33. g-h) The combination of SPP1 (g), THBS2 (h) and IGF2 (i)
- 3 signaling is specific to the EMT niche. Black box: EMT niche.



1

2 Extended data figure 5 related to figure 5. a) Median elastin and collagen levels

- 3 surrounding cell types in section 4. Dotted lines indicate the global median elastin (horizontal)
- 4 and collagen (vertical) levels. **b**) Dotplot of selected marker genes per fibroblast
- 5 transcriptomic cluster. Dot size: percentage of cells expressing the gene. Dot color: scaled
- 6 average expression. c) Spatial distribution of fibroblast clusters (section 4). d) Fibroblast
- 7 transcriptomic states are linked with their 3D neighborhoods. Heatmap showing enrichment
- 8 of fibroblast clusters in 3D niches. log2 fold changes are computed from the ratio between the
- 9 observed and expected number of cells per cluster in each 3D niche. e) Fibroblast states are

- 1 linked with ECM remodeling. Quantification of collagen and elastin (section 3) in fibroblast
- 2 neighborhoods (section4). f) Myofibroblasts underlie the production of stromal factors
- 3 specific to the EMT niche. Expression dotplot for EMT niche-specific fibroblast genes per
- 4 fibroblast transcriptomic cluster. Dot size: percentage of cells expressing the gene. Dot color:
- 5 scaled average expression. g) Cellular players of EMT niche signaling network. Dotplot of
- 6 cell type-specific percentages of involved cells (dot size) and log10 average ligand sender
- 7 (orange) and corresponding receptor receiver (blue) scores for ligands enriched in the EMT
- 8 niche. h-l) FN1 (h), THBS1 (i) and COL4A1 (l) 3D spatial activity scores. Black box: EMT
- 9 niche.





2 Figure 6. 3D neighborhoods boost the identification of immune niche-specific 3 interactions, including druggable immune checkpoints. a) Heatmap showing enrichment 4 of cell types in 3D niches. log2 fold changes are computed from the ratio between the 5 observed and expected number of cells per cluster in each 3D niche. b) 3D spatial density plot 6 of cytotoxic T cells, demonstrating their accumulation in immune niches and exclusion from 7 the tumor bed. c) Spatial organization of immune niches in the TME. 3D rendering of 8 'Dendritic cell niches' (purple), 'Macrophage niches' (magenta), 'T cell niches' (blue) and the 9 tumor bed (gray). d) Systematic scoring of interactions identifies ligands enriched in immune 10 niches. log2 Fold changes (log2 FC) for 164 ligands in 'Dendritic cell niches' (x axis) and 'Macrophage niches' (y axis). FC are computed comparing average ligand sender scores for 11 12 cells inside immune niches against those outside. 11 ligands with a log2FC > 0.75 in either 13 niche (red) and PD-L1 (dark grey) are labeled. Arrows connect 2D (dots) and 3D (triangles)

- 1 enrichment scores for each enriched ligand and PD-L1. e-g) CCL19 (e), LGALS9 (f) and
- 2 CD80 (g) signaling is enriched in immune niches. **h**) Cellular interactions driving tumor
- 3 invasion and immune escape, revealing mechanism-based personalized targets for cancer
- 4 interception. Summary scheme of selected molecular features and interaction in the 'EMT
- 5 niche' (left) and 'Dendritic cell niche' (right). The pill symbol indicates druggable
- 6 interactions.



2 Extended data figure 6 related to figure 6. a) log2 Fold changes (log2 FC) for 164 ligands 3 in 'Dendritic cell niches' (x axis) and T cell niches' (y axis). FC are computed comparing 4 average ligand sender scores for cells inside immune niches against those outside. 14 ligands 5 with a  $\log 2FC > 0.75$  in either niche (red) and PD-L1 (dark gray) are labeled. Arrows connect 6 2D (dots) and 3D (triangles) enrichment scores for each enriched ligand and PD-L1. b-c) 7 CCL21 (b) and CXCL9 (c) 3D spatial activity scores d) Cellular players of Dendritic cell 8 niche signaling network. Dotplot of cell type-specific percentages of involved cells (dot size) 9 and log10 average ligand sender (orange) and corresponding receptor receiver (blue) scores 10 for ligands enriched in Dendritic cell niche. e) MIF 3D spatial activity scores f) IDO1 is upregulated upon CD80-CTLA4 interaction. Differential gene expression between dendritic 11

- 1 cells engaged in CD80-CTLA4 interaction vs those not engaged. Red: genes with more > 5%
- 2 expression difference, labeled: top 3 differential genes.